US20060009811A1 - Ischemia detection - Google Patents
Ischemia detection Download PDFInfo
- Publication number
- US20060009811A1 US20060009811A1 US11/215,710 US21571005A US2006009811A1 US 20060009811 A1 US20060009811 A1 US 20060009811A1 US 21571005 A US21571005 A US 21571005A US 2006009811 A1 US2006009811 A1 US 2006009811A1
- Authority
- US
- United States
- Prior art keywords
- heart
- signal
- ischemia
- accelerometer
- electrical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
- A61B5/1107—Measuring contraction of parts of the body, e.g. organ, muscle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
- A61B5/339—Displays specially adapted therefor
- A61B5/341—Vectorcardiography [VCG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
- A61B5/346—Analysis of electrocardiograms
- A61B5/349—Detecting specific parameters of the electrocardiograph cycle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
- A61B5/346—Analysis of electrocardiograms
- A61B5/349—Detecting specific parameters of the electrocardiograph cycle
- A61B5/358—Detecting ST segments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7203—Signal processing specially adapted for physiological signals or for diagnostic purposes for noise prevention, reduction or removal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/368—Heart stimulators controlled by a physiological parameter, e.g. heart potential comprising more than one electrode co-operating with different heart regions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/02—Details of sensors specially adapted for in-vivo measurements
- A61B2562/028—Microscale sensors, e.g. electromechanical sensors [MEMS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/22—Arrangements of medical sensors with cables or leads; Connectors or couplings specifically adapted for medical sensors
- A61B2562/221—Arrangements of sensors with cables or leads, e.g. cable harnesses
- A61B2562/222—Electrical cables or leads therefor, e.g. coaxial cables or ribbon cables
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6867—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive specially adapted to be attached or implanted in a specific body part
- A61B5/6869—Heart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/36514—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure
- A61N1/36542—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure controlled by body motion, e.g. acceleration
Definitions
- the invention relates to cardiac health and, more particularly, to techniques for detection of myocardial ischemia.
- Myocardial ischemia a leading cause of mortality, involves oxygen starvation of the myocardium. Myocardial ischemia can lead to myocardial infarction if left untreated. Early detection of myocardial ischemia provides the opportunity for a wide range of effective therapies such as surgical revascularization, neural stimulation, and drug delivery to reduce cardiac workload or improve cardiac circulation. Unfortunately, many episodes of myocardial ischemia do not cause excessive pain or other noticeable warning signs, and often go undetected.
- An electrocardiogram (ECG) or electrogram (EGM) presents a PQRST waveform sequence that characterizes the cyclical cardiac activity of a patient.
- the T-wave can be used to identify an ischemic condition.
- U.S. Pat. No. 6,016,443 to Ekwall et al. describes an implantable ischemia detector that employs a repolarization sensor and a patient workload sensor to identify ischemic episodes.
- the repolarization sensor detects T-wave amplitude or duration to identify increased heart rate.
- the workload sensor detects patient activity such as exercise by monitoring body movement, muscle sounds, fluid pressure waves, or metabolic changes. When the T-wave indicates an increased heart rate, without a corresponding increase in workload, the detector identifies an ischemic condition.
- the ST segment also associated with the repolarization of the ventricles, is typically close in amplitude to the baseline, i.e., isoelectric amplitude, of the signal sensed between consecutive PQRST sequences.
- the ST segment amplitude deviates from the baseline. Accordingly, deviation in the ST segment is often used to identify an occurrence of myocardial ischemia.
- U.S. Pat. No. 6,021,350 to Mathson describes an implantable heart stimulator having an ischemia detector that indicates an ischemic condition based on elevation of the ST-segment above a baseline.
- the ischemia detector may rely on a measure of heart activity or patient workload.
- the stimulator controls the rate of stimulation based on the detection of ischemia using either of the alternative detection modes.
- the use of the ST segment as an indicator of ischemia can be unreliable.
- the ST segment may deviate from the baseline due to other factors, causing false indications of myocardial ischemia.
- the ST segment may deviate from the baseline due to changes in the overall PQRST complex, possibly caused by axis shifts, electrical noise, cardiac pacing stimuli, drugs and high sinus or tachycardia rates that distort the PQRST complex. Consequently, the reliability of the ST segment as an indicator of myocardial ischemia can be uncertain.
- U.S. Pat. No. 6,128,526 to Stadler et al. describes an ischemia detector that observes variation in the ST segment to identify an ischemic condition. To improve reliability, the detector is designed to filter out ST segment variations caused by factors other than ischemia, such as axis shift, electrical noise, cardiac pacing, and distortion in the overall PQRST complex.
- the invention is directed to techniques for more reliable detection and treatment of myocardial ischemia.
- the invention correlates electrical activity and dynamic mechanical activity of a heart to detect and verify the occurrence of myocardial ischemia in a more reliable manner.
- the electrical activity may be represented by the ST segment.
- the dynamic mechanical activity may be represented by a heart acceleration or pressure signal.
- Heart acceleration or pressure provides an indication of heart contractility.
- contractility generally refers to the ability of the heart to contract, and may indicate a degree of contraction. Heart contractility typically decreases during ischemic episodes.
- the invention determines whether a change in the ST segment is accompanied by a corresponding change in the contractility of the heart. Correlation of changes in the contractility of the heart with changes in the ST segment provides a more reliable indication of ischemia, reducing the incidence of false indications due to ST segment changes that are unrelated to ischemic conditions.
- Changes in the ST segment can be detected from an ECG, EGM, or subcutaneous electrode array (SEA). Changes in the dynamic mechanical activity of the heart can be obtained from an accelerometer or pressure transducer.
- the accelerometer produces an acceleration signal indicative of heart wall acceleration within a chamber of the heart.
- the pressure transducer produces a pressure signal indicative of right ventricular, left ventricular, or arterial pressure, depending upon the location of the pressure transducer.
- the electrical signal can be obtained from a set of implanted or external electrodes.
- an accelerometric signal can be obtained from an accelerometer deployed within or near the heart.
- the accelerometer transduces heart contractions into one or more accelerometric signals.
- the pressure signal can be obtained from a pressure transducer deployed within the heart or vasculature. Alternately, the pressure sensor could be positioned around a blood vessel.
- the accelerometer can be disposed at the distal tip of an implanted lead that is deployed within a chamber of the heart.
- the pressure transducer can be realized by a cardiac pressure lead.
- a signal processing circuit can be used to detect drops in contractility during myocardial ischemia by comparing the accelerometric or pressure signal to a criterion such as a predetermined threshold.
- the invention correlates contractility changes derived from signals generated by a lead tip accelerometer or cardiac pressure lead with changes in the ST segment to increase the specificity of ischemia detection.
- the utilization of a lead tip accelerometer or pressure lead in conjunction with electrical detection permits differentiation between ST segment changes accompanied by changes in cardiac contractility and ST segment changes without significant changes in cardiac contractility. Changes in cardiac contractility derived from the accelerometer or pressure lead provide another indication of ischemic conditions, and confirm the indication provided by the ST segment.
- the invention provides a method for detecting myocardial ischemia, the method comprising obtaining a first signal indicative of dynamic mechanical activity of a heart, obtaining a second signal indicative of electrical activity of the heart, and detecting myocardial ischemia based on both the first signal and the second signal.
- the invention also may provide computer-readable media carrying instructions for performing the method.
- the invention provides a system for detecting myocardial ischemia, the system comprising a first sensor that generates a first signal indicative of dynamic mechanical activity of a heart, a second sensor that obtains a second signal indicative of electrical activity of the heart, and a processor that detects myocardial ischemia based on both the first signal and the second signal.
- the invention provides a method for detecting myocardial ischemia, the method comprising obtaining a first signal indicative of contractile activity of a heart, obtaining a second signal indicative of electrical activity of the heart, and detecting myocardial ischemia based on both the first signal and the second signal.
- the invention also may provide computer-readable media carrying instructions for performing the method.
- the invention provides a system for detecting myocardial ischemia, the system comprising means for generating a first signal indicative of contractile activity of a heart, means for obtaining a second signal indicative of electrical activity of the heart, and means for detecting myocardial ischemia based on both the first signal and the second signal.
- the invention is capable of providing a number of advantages. For example, correlation of changes in heart contractility with changes in the ST segment provide a more reliable indication of an ischemic event. In this manner, the invention is useful in increasing the specificity of ischemia detection, generally avoiding false indication of ischemic events due to axis shifts, electrical noise, cardiac pacing stimuli, high sinus or tachycardia rates, or other factors that undermine the effectiveness of a purely electrical detection technique. Also, the invention is capable of improving sensitivity to ischemic episodes by allowing the detection of ischemia when either the mechanical or the electrical signals are indicative of ischemia.
- the invention can be useful in quantifying a degree of ischemic tissue according to a degree of cardiac contractility and a degree of change in the ST segment.
- the combination of electrical and mechanical monitoring of heart activity can aid in determining the location of ischemic tissue.
- both the electrical and mechanical signals can be monitored along multiple axes.
- the electrical signal may include multiple electrical signals obtained from different lead sets, whereas an accelerometer may be sensitive along two and perhaps three axes.
- multiple accelerometers or pressure sensors can be used to achieve sensitivity along multiple axes.
- FIG. 1 is a diagram illustrating an exemplary implantable medical device in association with a heart.
- FIG. 2 is a diagram illustrating another exemplary implantable medical device in association with a heart.
- FIG. 3 is a side view illustrating an implantable lead suitable for incorporation of a lead-tip accelerometer.
- FIG. 4 is a cross-sectional side view of the lead shown in FIG. 3 .
- FIG. 5 is a block diagram illustrating a system for detection of ischemia.
- FIGS. 6A, 6B , and 6 C are graphs illustrating the relationship between electrical activity and heart acceleration within a canine heart.
- FIGS. 7A, 7B , and 7 C are graphs illustrating the relationship between electrical activity and heart acceleration within a canine heart during an episode of ischemia.
- FIG. 8 is another graph illustrating changes in heart acceleration in the presence of ischemia.
- FIG. 9 is a flow diagram illustrating a process for ischemia detection.
- FIG. 10 is a flow diagram illustrating another process for ischemia detection.
- FIG. 11 is a flow diagram illustrating a process for ischemia detection in greater detail.
- FIG. 1 is a diagram illustrating an implantable medical device (IMD) 10 in association with a heart 34 .
- IMD 10 may be configured for both monitoring and therapy of heart 34 .
- IMD 10 may include a pulse generator to deliver electrical stimulation to heart 34 for use in cardioversion or defibrillation.
- IMD 10 obtains a signal indicative of dynamic mechanical activity of heart 34 , and an electrical signal indicative of electrical activity of the heart.
- IMD 10 uses both signals, i.e., the electrical signal and the signal indicative of dynamic mechanical activity to detect the existence of myocardial ischemia within heart 34 .
- both signals reveal ischemic conditions, IMD 10 indicates an ischemic episode.
- the signal indicative of dynamic mechanical activity corroborates the electrical signal.
- IMD 10 can be configured to deliver appropriate therapy to alleviate its effects.
- the therapy may include drug delivery, electrical stimulation, or both.
- IMD 10 may determine the location of ischemic tissue and the severity of the ischemic condition, providing more specific information that may be useful in selection of treatment.
- IMD 10 may be generally flat and thin to permit subcutaneous implantation within a human body, e.g., within upper thoracic regions or the lower abdominal region.
- IMD 10 may include a hermetically sealed housing 14 having a connector block assembly 12 that receives the proximal ends of one or more cardiac leads for connection to circuitry enclosed within housing 14 .
- connector block assembly 12 receives a ventricular endocardial lead 28 .
- ventricular endocardial lead 28 may include an accelerometer to obtain a heart acceleration signal or a pressure transducer to obtain a pressure signal.
- a pressure signal can be obtained from outside a blood vessel, e.g., with the use of implantable blood vessel cuffs as described in U.S. Pat. Nos. 6,010,477 and 6,077,277 to Miesel et al.
- multiple accelerometers or pressure sensors can be used to achieve sensitivity along multiple axes. For instance, if a coronary artery providing oxygen to the left side of the heart is occluded, there may be a decrease in accelerometer—or pressure sensor-indicated contractility from a left-sided lead, but not necessarily from a lead in the right ventricle. This may be particularly the case for an accelerometer lead placed on the right ventricular free wall, which is not mechanically coupled to the left ventricle, as well as a lead placed on the ventricular septum. Accordingly, multiple sensors may be desirable for enhanced sensitivity.
- Ventricular endocardial lead 28 may be, for example, a bipolar, two wire lead equipped to sense electrical signals.
- An accelerometer can be incorporated adjacent a distal tip 30 of lead 28 , and thereby deployed within heart 34 .
- housing 14 may enclose circuitry for use in analyzing the heart acceleration signal produced by the accelerometer, and electrical signals such as ECGs or EGMs obtained by IMD 10 to detect ischemia within heart 34 .
- IMD 10 may include a plurality of EGM sense electrodes 16 , 18 , 20 , 22 , 24 , 26 .
- EGM sense electrodes 16 , 18 , 20 , 22 , 24 , 26 may be arranged substantially as described in U.S. Pat. No. 6,128,526, to Stadler et al., entitled “METHOD FOR ISCHEMIA DETECTION AND APPARATUS USING SAME,” the entire content of which is incorporated herein by reference.
- electrodes 16 , 18 , 20 , 22 , 24 , 26 may form a plurality of sense electrode pairs that are integrated with the exterior of housing 12 of IMD 10 .
- the sense electrode pairs can be used to obtain electrical signals along one or more sensing axes to formulate one or more EGM signals.
- the EGM signal obtained via sense electrodes 16 , 18 , 20 , 22 , 24 , 26 together with the heart acceleration signal provided by an accelerometer or pressure transducer, can be used to detect ischemia, as well as the degree of ischemia and the location of ischemic tissue within heart 34 .
- the accelerometer provides an indication of the dynamic mechanical activity of the heart, which either reinforces or negates an indication of ischemia derived from a change in the electrical signal.
- the heart acceleration signal can be used to measure other events in different frequency ranges.
- the heart acceleration signal may be monitored from 0 to 0.5 Hz for the patient's posture or orientation, from 1 to 5 Hz for the patient's activity, e.g., exercise, and from 5 to 100 Hz for the patient's heart acceleration.
- the frequency range for analysis of heart acceleration is the range useful in identification of ischemia.
- the accelerometer may serve multiple purposes. For example, by analyzing the pertinent frequency bands, the accelerometer may be used to detect patient activity, patent orientation, and heart acceleration.
- a programmer/output device 44 with an antenna 46 can be provided for wireless communication with IMD 10 .
- IMD 10 may include a telemetry circuit that transmits radio frequency messages, which may include indications of ischemia and other information to device 44 .
- IMD 10 also may receive programming information via the telemetry circuit for modification of operational parameters within the IMD.
- Device 44 also may include a display for graphic or textual presentation of information transmitted by IMD 10 , as well as a visible or audible annunciator that provides an indication of the detection of ischemia within heart 34 .
- IMD 10 also may be equipped with an alarm for notification of the patient in the event ischemia is detected.
- device 44 may include a user input device, such as a keypad, by which a physician may modify operational parameters for use in programming IMD 10 for diagnosis or treatment.
- FIG. 2 is a diagram illustrating another IMD 48 in association with a human heart 34 .
- IMD 48 may be configured to provide electrical stimuli to heart 34 for defibrillation.
- IMD 48 may generally conform to the defibrillation system described in the above-referenced U.S. Pat. No. 6,128,526.
- IMD 48 includes an outer housing 54 that functions as an electrode, along with a set of electrodes 52 , 56 , 58 provided at various locations on the housing or connector block 50 .
- IMD 48 may include leads 60 , 62 for deployment of defibrillation coil electrodes 64 , 70 within two chambers of heart 34 .
- Leads 60 , 62 may include additional electrodes, such as electrodes 66 , 68 , 72 , 74 , for sensing of electrical activity within heart 34 .
- Electrodes 66 , 68 , 72 , 74 may form electrode pairs with respective electrodes 52 , 56 , 58 on IMD 48 .
- an accelerometer can be mounted in one of leads 60 , 62 to obtain a heart acceleration signal for use in detecting ischemia.
- the heart acceleration signal may be derived from left-sided leads deployed via the coronary sinus.
- a pressure sensor may be used in lieu of the accelerometer in some embodiments.
- FIG. 3 is a side view illustrating an implantable lead 76 equipped with a lead-tip accelerometer.
- Lead 76 may be configured for use as a diagnostic lead, therapeutic lead, or both, and may be incorporated with a variety of IMDs including those shown in FIGS. 1 and 2 .
- lead 76 may carry sense electrodes, stimulation electrodes, or both.
- lead 76 may include a distal tip 78 , a first section 80 , and a second section 82 .
- First and section sections 80 , 82 include outer walls 81 , 83 , respectively, formed of nonconductive, biocompatible material.
- Distal tip 78 may include an electrode 84 , as well as a number of stabilizing tines (not shown in FIG. 3 ) for securing distal tip member 78 in cardiac tissue upon deployment.
- lead 76 may include electrical conductors which may be coupled to electrode 84 and an accelerometer assembly mounted within second section 82 .
- FIG. 4 is a cross-sectional side view of lead 76 shown in FIG. 3 .
- FIG. 4 shows first section 80 , second section 82 , distal tip 78 , electrode 84 .
- Stabilizing tines or other anchoring structure may be added to distal tip 78 , if desired.
- lead 76 includes an accelerometer assembly 88 mounted within second section 82 adjacent distal tip 78 .
- Accelerometer assembly 88 forms a capsule, and includes an accelerometer that may be fabricated using microelectromechanical systems (MEMS) technology, providing high tolerance and very small size.
- MEMS microelectromechanical systems
- accelerometer assembly 88 may be used in a bipolar lead system, reducing accelerometer assembly size and increasing reliability.
- Lead 76 also includes conductors in the form of first and second conductive coiled conductors 90 , 92 , which are arranged coaxially along the length of the lead.
- Coiled conductors 90 , 92 may be coupled to distal electrode 84 and accelerometer assembly 88 to carry electrical current to and from the electrode and accelerometer assembly to a proximal end of the lead, which may be coupled to an IMD.
- inner coiled conductor 90 may be coupled to interior components of accelerometer assembly 88 via a feedthrough assembly 86 .
- Outer coiled conductor 92 may be coupled to the exterior housing of accelerometer assembly 88 , which is electrically conductive and may be formed from titanium, and to electrode 84 .
- the accelerometer signal may be produced between conductors 90 , 92 via an internal accelerometer connection and the exterior housing connecting, respectively.
- the signal from electrode 84 may be produced between conductor 92 and an electrode on the IMD housing or “can.”
- Distal tip 78 , first section 80 , and second section 82 are crimped together at crimp points indicated generally by reference numerals 94 , 96 , 98 .
- An adhesive material 99 fills the void within feedthrough assembly 86 .
- the heart acceleration signal varies as a function of the contractile force of heart 34 .
- the contractile force is transduced by accelerometer assembly 88 to produce an electrical heart acceleration signal that represents the contractility of the heart and, more generally, the dynamic mechanical activity of the heart.
- the contractile force of heart 34 physically deforms the accelerometer in assembly 88 to change its electrical properties, and modulate the current passing through the accelerometer.
- an indication of heart contractility can be obtained alternatively using a pressure transducer.
- Accelerometer assembly 88 can make use of conventional accelerometer technology and may take the form of a piezoelectric, piezoresistive, capacitive, inductive, or magnetic sensor that produces a change in an electrical property with changes in accelerometric force within heart 34 .
- the changes in the electrical property e.g., resistance, capacitance, inductance, and the like, in turn produces changes in the electrical signal produced by accelerometer assembly 88 .
- accelerometer assembly 88 is mounted at the tip or distal end of lead 76 .
- Accelerometer assembly 88 could be mounted elsewhere within lead 76 , however, provided it can be properly positioned and oriented to detect accelerometric force produced by the contractile activity of heart 34 .
- accelerometer assembly 88 may be formed to have either one, two, or three detection axes. In other words, accelerometer assembly 88 may be configured to detect accelerometric force extending in multiple directions as a result of the contractile force generated by different walls within heart 34 .
- accelerometer assembly 88 may be equipped with a multi-axis accelerometer or multiple accelerometers oriented orthogonally in relation to the respective axes, as well as multiple conductors for obtaining the heart acceleration signal as output from each respective accelerometer.
- accelerometer assembly 88 could include a single conductor line that carries current to multiple accelerometers, and two or more additional conductor lines that return current from each of the accelerometers to provide separate heart acceleration signal outputs for the different axes.
- each accelerometer may be coupled to the same conductor lines, and produce signals that are time-multiplexed to distinguish the output of each accelerometer.
- Detection of heart acceleration along multiple axes may be useful in determining the location of ischemic tissue. If the heart acceleration signal along one axis is “normal,” i.e., not indicative of ischemia, whereas the heart acceleration signal along another axis indicates a possible episode of ischemia, the location of the ischemic tissue can be determined according to the orientation of the axis along which the pertinent accelerometer is aligned.
- the ischemic condition can be treated, by intervention of a physician or in an automated manner, and targeted to an appropriate region of heart 34 .
- electrical stimulation can be delivered to a selected stimulation electrode best suited for treatment of the affected location.
- the amplitude, frequency, or pulse width of stimulating current can be controlled according to the affected location to achieve an optimum therapeutic effect.
- determination of the location of ischemic tissue can be used to choose other types of therapy such as drug delivery, as well as types, dosages and durations of drug delivery.
- the location information can be compared to location information recorded in the past to determine whether the ischemia is occurring in a new location or a location of prior ischemic episodes.
- FIG. 5 is a block diagram illustrating a system 100 for detection of ischemia.
- system 100 may include a lead selector circuit 102 that selects one or more lead pairs 104 , a signal processor circuit 106 , an accelerometer 108 , a processor 110 , memory 112 , a therapy control circuit 112 , a therapy delivery system 114 , and a telemetry device 116 with an antenna 118 .
- Lead selector circuit 102 may be controlled by processor 110 , and select lead pairs for acquisition of electrical signals oriented along multiple detection axes relative to heart 34 .
- Processor 110 may take the form of a microprocessor, microcontroller, digital signal processor (DSP) or other programmable logic device.
- the electrical signals obtained via the lead pairs can be used to formulate an ECG or EGM for analysis of the PQRST complex and, in particular, the ST segment. Changes in the ST segment can be an indicator of ischemia. Analysis of the dynamic mechanical activity of the heart in combination with changes in the ST segment, according to the invention, can provide a more reliable indication of ischemia.
- Signal processor circuit 106 receives the output of lead selector circuit 102 and a heart acceleration signal from an accelerometer 108 , which may be deployed in a lead tip as described with reference to FIGS. 3 and 4 .
- signal processor circuit 106 may receive a pressure signal from a pressure transducer.
- the output of lead selector circuit 102 may be three electrode pair signals, such as RV coil-can, RV ring-can, and SVC coil-can.
- accelerometer 108 may produce multiple heart acceleration signals oriented along similar detection axes.
- Signal processor circuit 106 may include a number of sense amplifiers that amplify the ECG or EGM signals, as well as the heart acceleration signal.
- signal processor circuit 106 may include sampling and comparator circuitry for analysis of the electrical signals and heart acceleration signals relative to criteria such as average, peak-to-peak, or total amplitude thresholds.
- processor 110 may digitally sample the signals amplified by signal processor circuit 106 and perform a software-based analysis of the digital signals.
- signal processor circuit 106 may include an analog-to-digital converter that converts the analog signals produced by lead selector circuit 102 and accelerometer 108 into digital samples for analysis by processor 110 .
- Processor 110 may provide the necessary control and clock signals for operation of signal processor circuit 106 .
- a memory 112 is provided for storage of digital samples produced by signal processor circuit 106 and intermediate data stored and retrieved by processor 110 .
- signal processor circuit 106 may include a number of buffers that hold digital samples for storage in memory.
- processor 110 , memory 112 , and signal processor 106 may communicate via a common data and instruction bus, as is well known in the art.
- the digital samples may be parameterized, in signal processor circuit 106 or processor 110 , to produce values for comparison to a predetermined threshold. Again, the comparison may take place within discrete circuitry provided by signal processor circuit 106 or via code executed by processor 110 .
- the code may include instructions carried by a computer-readable medium accessible by processor 110 , such as memory 112 or other fixed or removable media devices associated with an external programmer/output device communicatively coupled to the processor via telemetry device 116 .
- ECG, EGM, SEA or other electrical signals produced by lead selector circuit 102 can be processed and parameterized to represent a variety of different values useful in the comparison.
- the electrical signals may be processed to produce an amplitude value, such as an average, peak-to-peak, or total amplitude, for the ST segment of the PQRST complex.
- the ST segment is typically close in amplitude to the baseline of the ECG or EGM signal sensed between consecutive PQRST sequences. During episodes of myocardial ischemia, however, the ST segment amplitude may increase or decrease substantially.
- processor 110 can identify a potential episode of ischemia.
- processor 110 may be configured to detect a location of the ischemic condition based on which one of the lead pairs produces an ST segment excursion above the amplitude threshold.
- the location may be correlated with one of several acceleration signals obtained from accelerometer 108 for different sensing axes.
- An average amplitude may be obtained and represented in a number of ways such as by computing the average of a series of samples over the period of time coincident with the ST segment.
- a peak-to-peak amplitude for each signal can be obtained by detection of maxima and minima of the ST segment and detection of maxima and minima of a heart acceleration signal over a duration of time that generally coincides with the ST segment.
- a total amplitude for each signal can be obtained by integrating the ST segment and integrating the acceleration signal over a duration of time that generally coincides with the ST segment. Also, because the change in the ST segment may be elevated or depressed during an ischemic episode, the ST segment parameter may rely on the absolute value of the change in the ST segment.
- processor 110 (and/or signal processor circuit 106 ) is also configured to analyze the heart acceleration signal produced by accelerometer 108 .
- processor 110 compares a parameterized value representative of the heart acceleration signal, such as an average amplitude or integrated amplitude, at a time substantially coincident with the ST segment to a pertinent threshold. In this manner, system 100 is capable of correlating the ST segment and the heart acceleration signal for more reliable detection of ischemia.
- processor 110 By verifying whether the heart acceleration signal (or alternatively a pressure signal) also indicates ischemia, processor 110 is able to disregard deviations in the ST segments due to conditions other than ischemia, e.g., due to changes in the overall PQRST complex caused by axis shifts, electrical noise, cardiac pacing stimuli, drugs, and high sinus or tachycardia rates that distort the PQRST complex. Consequently, system 100 is capable of reducing the number of false indications of ischemia, and increasing the reliability of the ST segment as an indicator of myocardial ischemia.
- processor 110 Based on deviation of the ST segment and the heart acceleration signal relative to the pertinent thresholds, processor 110 also may quantify the severity of the ischemic condition. If the ST segment and the heart acceleration signal both satisfy the pertinent thresholds, processor 110 indicates an ischemic event, and may be programmed to effect therapeutic action. For example, processor 110 may generate a therapy control signal that causes a therapy control circuit 112 to request delivery of therapy from a therapy delivery system 114 .
- Therapy delivery system 114 may take, for example, the form of a drug delivery system or electrical stimulation system such as a cardioversion or defibrillation circuit.
- Processor 110 also may indicate to therapy control circuit 112 the location of the ischemic tissue and the severity of the ischemic condition based on the accelerometer signal. Accordingly, therapy control circuit 112 may be configured to control therapy delivery system 114 based on the indications provided by processor 110 . For example, therapy control circuit 112 may select the type of therapy, e.g., drug delivery and/or electrical stimulation, the dosage, amplitude, and duration of the therapy, as well as the location for delivery of the therapy, based on the indications of location and severity provided by processor 110 .
- therapy control circuit 112 may select the type of therapy, e.g., drug delivery and/or electrical stimulation, the dosage, amplitude, and duration of the therapy, as well as the location for delivery of the therapy, based on the indications of location and severity provided by processor 110 .
- Processor 110 also may control a telemetry device 116 to communicate an indication of the ischemic condition to an external device via antenna 118 .
- the indication may be a wireless, radio frequency message that indicates an ischemic condition and, in some embodiments, the location of the ischemic tissue and the severity of the ischemic condition.
- the IMD itself may have an audible alarm that notifies the patient when an ischemic episode is occurring.
- the external device advises a physician or other attendant of the ischemic condition, e.g., via a display or a visible or audible alarm.
- the ischemic events may be stored in memory in the external device, or within the IMD, for review by a physician.
- the components of system 100 may be housed in a common housing such as those shown in FIGS. 1 and 2 . Alternatively, portions of system 100 may be housed separately.
- therapy delivery system 114 could be provided in a separate housing, particularly where the therapy delivery system includes drug delivery capabilities. In this case, therapy control circuit 112 may interact with therapy delivery system 114 via an electrical cable or wireless link.
- FIGS. 6A, 6B , and 6 C are graphs illustrating an example relationship between electrical activity and heart acceleration within a canine heart.
- FIG. 6A shows an ECG signal, including the R-wave peak, ST segment and T-wave over a period of time.
- FIG. 6B shows the output of a pressure sensor positioned within the left ventricle, e.g., in a lead deployed within the ventricle, over the same period of time.
- FIG. 6C shows the output of an accelerometer positioned within the right ventricle, e.g., at the tip of a lead deployed within the ventricle, also over the same period of time.
- the heart acceleration signal is characterized by a section 120 that generally coincides in time with the ST segment of the ECG signal.
- the pressure signal has a section 121 that coincides with the ST segment.
- sections 120 , 121 are characterized by a momentary positive excursion followed by a negative excursion, which correspond to the contractile forces of the left ventricle.
- the increase in pressure is due to the pressure developed during contraction.
- the pressure drops during relaxation.
- the acceleration signal the increase is due to the heart's acceleration or vibration during contraction, with the acceleration signal occurring during the same time as the maximum slope of the pressure signal (DP/DT).
- a second acceleration signal typically of a lower amplitude than the first acceleration signal and corresponding to the maximum negative DP/DT, also can be seen.
- the waveforms may vary significantly, however, depending on the location of the lead, the accelerometer sensitivity axis, and other factors.
- FIGS. 6A and 6C also illustrate example amplitude thresholds T 1 and T 2 .
- the thresholds may be used in analysis of the ST segment amplitude and heart acceleration signal amplitude, respectively. A similar threshold can be used for the pressure signal.
- the thresholds may reflect an average amplitude over the duration of the ST segment or a peak-to-peak amplitude.
- total amplitudes obtained, e.g., by integration of the heart acceleration signal could be used for comparison to total amplitude thresholds.
- thresholds T 1 and T 2 represent peak-to-peak amplitude thresholds for comparison to the maxima and minima of the ST segment and heart acceleration signal, respectively.
- FIGS. 7A, 7B , and 7 C are graphs illustrating an example relationship between electrical activity and heart acceleration within a canine heart during an episode of ischemia.
- the ST segment of an ECG or EGM signal may show a significant increase when the heart tissue becomes ischemic.
- the amplitude of the ST segment in FIG. 7A is markedly increased, and exceeds the threshold T 1 , which may be specified by a physician for identification of ischemic conditions.
- the amplitude of the pressure signal is decreased relative to that shown in FIG. 6B .
- the heart acceleration signal also shows the effects of ischemia.
- the section 120 of the heart acceleration signal that coincides with the ST segment is markedly decreased in amplitude relative to FIG. 6C .
- section 120 has a peak-to-peak amplitude that is less than the threshold T 2 .
- the amplitudes of the ST segment and heart acceleration signal may be peak-to-peak, average, or total amplitudes, or any other parameter deemed reliable in detection of ischemia.
- the basic technique simply involves analysis of both the ST segment and the heart acceleration signal in a correlative manner to reduce the possibility that changes in the ST segment are due to factors other than ischemia. This enables a reduction in the number of false indications.
- FIG. 8 is another graph illustrating changes in heart acceleration in the presence of ischemia.
- FIG. 8 illustrates changes in the heart acceleration signal 122 during an experiment in which ischemia is induced in a canine heart.
- the left axis of the graph shows the accelerometer peak-to-peak signal, measured in gravitational gs.
- the bottom axis shows the progression of time.
- the right axis shows an ischemia parameter 124 .
- the ischemia parameter 124 can be derived from, for example, an electrical signal such as the ST segment of an ECG or EGM signal.
- ischemia parameter 124 may represent the ST segment change as a percentage of the R-wave amplitude.
- the heart acceleration signal 122 peaks sharply, as the dobutamine induces a forceful contraction in the heart. Later, the heart is subjected to balloon occlusion to intentionally limit the flow of blood, and thereby induce ischemia. At that time, the ischemia parameter peaks sharply, as indicated by reference numeral 125 , whereas the heart acceleration signal 122 drops noticeably, as indicated by reference numeral 128 . When the balloon occlusion is again applied, as indicated by reference numeral 126 , the heart acceleration signal 122 again drops while the ischemia parameter peaks.
- the vertical dashed lines in FIG. 8 denote the duration of the dobutamine infusion, first balloon occlusion, and second balloon occlusion.
- FIG. 9 is a flow diagram illustrating a process for ischemia detection.
- the process may include obtaining an electrical signal such as an ECG or EGM signal ( 130 ) and applying a first criterion to the signal ( 132 ).
- the first criterion may be an amplitude threshold that is compared to an amplitude parameter of the electrical signal, such as an average, peak-to-peak or total amplitude of the ST segment of the electrical signal. If the first criterion is not satisfied, the process returns to evaluation of the electrical signal ( 130 ).
- the technique involves obtaining an accelerometer signal, i.e., a heart acceleration signal ( 136 ), and applying a second criterion to the accelerometer signal ( 138 ).
- the second criterion may be an amplitude threshold that is compared to an amplitude parameter of the heart acceleration signal, such as an average, peak-to-peak, or total amplitude in a region that temporally coincides with the ST segment of the electrical signal.
- the process returns to evaluation of the electrical signal ( 130 ). If the second criterion is satisfied ( 140 ), however, the process indicates an ischemic episode ( 142 ).
- the process may respond to an indication of ischemia by delivering therapy to the patient ( 144 ).
- the process may involve drug delivery or electrical stimulation.
- the drug delivery and electrical stimulation may be delivered by an implantable medical device, including one that is integrated with ischemia detection circuitry. Alternatively, drug delivery and electrical stimulation may be administered to the patient externally.
- FIG. 10 is a flow diagram illustrating another process for ischemia detection.
- the process of FIG. 10 is similar to that of FIG. 9 , but illustrates the acquisition of multiple electrical signals for different axes to facilitate determination of the location of ischemic tissue.
- the process may involve obtaining multiple ECG signals ( 144 ), applying a first criterion to the signals ( 146 ), and determining whether the criterion is satisfied for any of the signals ( 148 ). If so, the process identifies the electrical signals that satisfy the criterion ( 150 ), and then obtains the accelerometer signal ( 152 ).
- the process Upon application of a second criterion to the accelerometer signal ( 154 ), and satisfaction of that criterion ( 156 ), the process indicates an episode of ischemia along with an indication of the location of ischemic tissue based on which of the electrical signals satisfied the first criterion ( 158 ), i.e., which of the electrical signals showed a change in the ST segment indicative of ischemia.
- the process may further involve delivery of therapy ( 160 ) and, in some embodiments, delivery of therapy to a particular location within the heart, or in a form selected for a particular location.
- Determination of the location of ischemic tissue within the heart also can be aided by obtaining multiple heart acceleration signals along multiple axes.
- the heart acceleration signals may indicate ischemia along one axis but not necessarily the others, enabling isolation of more specific region of ischemia within the heart. As with the electrical signals, this may aid in selection of the type, level, and focus of the therapy delivered to the patient.
- FIG. 11 is a flow diagram illustrating a process for ischemia detection in greater detail.
- the process may involve analysis of an electrical signal such as an ECG or EGM signal to identify the ST segment ( 162 ).
- the ST segment may be parameterized ( 164 ), e.g., as a peak-to-peak amplitude, average amplitude, or total amplitude, and compared to an amplitude threshold T 1 ( 166 ). If the ST segment amplitude exceeds the threshold T 1 , there is a potential ischemic condition.
- the process involves obtaining an accelerometer signal ( 168 ), parameterizing the accelerometer signal ( 170 ), and comparing it to an amplitude threshold T 2 ( 172 ). If the accelerometer signal amplitude drops below the threshold T 2 ( 172 ), a contractility change is confirmed in addition to the increase in the ST segment, providing a more reliable indication of ischemia. On this basis, the process indicates an ischemic condition ( 174 ) and may use the indication as the basis for delivery of therapy ( 176 ) to the patient.
- Amplitude thresholds are described herein for purposes of example, and are not to be read as limiting of the invention as broadly claimed. Other signal parameters may be appropriate for evaluation in identifying ischemia. Also, it is noted that exceeding a given threshold may refer to a change that results in an increase above or below a certain level, for example, as described with reference to the graphs of FIGS. 6, 7 , and 8 . Specifically, in some cases, ischemia may be indicated by an increase in the ST segment amplitude and a decrease in the heart acceleration signal at the time of the ST segment. Also, in some embodiments, the electrical and acceleration signals could be combined into a single parameterized value that is compared to a single threshold value to determine whether an ischemic episode is indicated.
- a signal indicative of dynamic mechanical heart activity to confirm an episode of ischemia indicated by the ST segment of an electrical signal can provide a number of advantages including more reliable indication of ischemia, avoidance of false indications and unnecessary administration of treatment.
- the heart acceleration signal may be useful, alone or in combination with the electrical signal, in more reliably quantifying the contractile function of the heart, and hence the degree of ischemia, providing a standard for the type or amount of therapy delivered to the patient.
- a multi-dimensional heart acceleration signal can be used to better identify the location of ischemic tissue.
- the use of a multi-axial accelerometer in a lead tip can detect axis shift due to postural changes and add sensitivity to the ischemia detection.
- the multi-axial accelerometer signals can be combined in a logical OR fashion to increase sensitivity to ischemia, or combined in a logical AND fashion to increase specificity, i.e., in terms of the location of the ischemic tissue.
- relative changes in the orthogonal accelerometer signals can be used to more narrowly identify the location of ischemic tissue.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Physics & Mathematics (AREA)
- Physiology (AREA)
- Signal Processing (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Artificial Intelligence (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Dentistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Electrotherapy Devices (AREA)
Abstract
Techniques for detection and treatment of myocardial ischemia are described that monitor both the electrical and dynamic mechanical activity of the heart to detect and verify the occurrence of myocardial ischemia in a more reliable manner. The occurrence of myocardial ischemia can be detected by monitoring changes in an electrical signal such as an ECG or EGM, and changes in dynamic mechanical activity of the heart. Dynamic mechanical activity can be represented, for example, by a heart acceleration signal or pressure signal. The electrical signal can be obtained from a set of implanted or external electrodes. The heart acceleration signal can be obtained from an accelerometer or pressure sensor deployed within or near the heart. The techniques correlate contractility changes detected by an accelerometer or pressure sensor with changes in the ST electrogram segment detected by the electrodes to increase the reliability of ischemia detection.
Description
- This patent document relates to co-pending application filed 30 Aug. 2001 having serial number 09/945,179 issued 30 Aug. 2005 as U.S. Pat. No. 6,937,899. This patent document relates to co-pending application filed 30 Aug. No. 6,937,899; entitled, “Ischemia Detection,” the entire contents of which are hereby incorporated by reference herein.
- The invention relates to cardiac health and, more particularly, to techniques for detection of myocardial ischemia.
- Myocardial ischemia, a leading cause of mortality, involves oxygen starvation of the myocardium. Myocardial ischemia can lead to myocardial infarction if left untreated. Early detection of myocardial ischemia provides the opportunity for a wide range of effective therapies such as surgical revascularization, neural stimulation, and drug delivery to reduce cardiac workload or improve cardiac circulation. Unfortunately, many episodes of myocardial ischemia do not cause excessive pain or other noticeable warning signs, and often go undetected.
- An electrocardiogram (ECG) or electrogram (EGM) presents a PQRST waveform sequence that characterizes the cyclical cardiac activity of a patient. The T-wave can be used to identify an ischemic condition. U.S. Pat. No. 6,016,443 to Ekwall et al., for example, describes an implantable ischemia detector that employs a repolarization sensor and a patient workload sensor to identify ischemic episodes. The repolarization sensor detects T-wave amplitude or duration to identify increased heart rate. The workload sensor detects patient activity such as exercise by monitoring body movement, muscle sounds, fluid pressure waves, or metabolic changes. When the T-wave indicates an increased heart rate, without a corresponding increase in workload, the detector identifies an ischemic condition.
- The ST segment, also associated with the repolarization of the ventricles, is typically close in amplitude to the baseline, i.e., isoelectric amplitude, of the signal sensed between consecutive PQRST sequences. During episodes of myocardial ischemia, the ST segment amplitude deviates from the baseline. Accordingly, deviation in the ST segment is often used to identify an occurrence of myocardial ischemia.
- U.S. Pat. No. 6,021,350 to Mathson, for example, describes an implantable heart stimulator having an ischemia detector that indicates an ischemic condition based on elevation of the ST-segment above a baseline. Alternatively, the ischemia detector may rely on a measure of heart activity or patient workload. The stimulator controls the rate of stimulation based on the detection of ischemia using either of the alternative detection modes.
- Unfortunately, the use of the ST segment as an indicator of ischemia can be unreliable. The ST segment may deviate from the baseline due to other factors, causing false indications of myocardial ischemia. For example, the ST segment may deviate from the baseline due to changes in the overall PQRST complex, possibly caused by axis shifts, electrical noise, cardiac pacing stimuli, drugs and high sinus or tachycardia rates that distort the PQRST complex. Consequently, the reliability of the ST segment as an indicator of myocardial ischemia can be uncertain.
- U.S. Pat. No. 6,128,526 to Stadler et al. describes an ischemia detector that observes variation in the ST segment to identify an ischemic condition. To improve reliability, the detector is designed to filter out ST segment variations caused by factors other than ischemia, such as axis shift, electrical noise, cardiac pacing, and distortion in the overall PQRST complex.
- Efforts to verify the reliability of the ST segment have generally proven complicated. Accordingly, there continues to be a need for a simplified system capable of automatically and reliably detecting myocardial ischemia.
- The invention is directed to techniques for more reliable detection and treatment of myocardial ischemia. In particular, the invention correlates electrical activity and dynamic mechanical activity of a heart to detect and verify the occurrence of myocardial ischemia in a more reliable manner.
- The electrical activity may be represented by the ST segment. The dynamic mechanical activity may be represented by a heart acceleration or pressure signal. Heart acceleration or pressure provides an indication of heart contractility. The term “contractility” generally refers to the ability of the heart to contract, and may indicate a degree of contraction. Heart contractility typically decreases during ischemic episodes.
- Accordingly, the invention determines whether a change in the ST segment is accompanied by a corresponding change in the contractility of the heart. Correlation of changes in the contractility of the heart with changes in the ST segment provides a more reliable indication of ischemia, reducing the incidence of false indications due to ST segment changes that are unrelated to ischemic conditions.
- Changes in the ST segment can be detected from an ECG, EGM, or subcutaneous electrode array (SEA). Changes in the dynamic mechanical activity of the heart can be obtained from an accelerometer or pressure transducer. The accelerometer produces an acceleration signal indicative of heart wall acceleration within a chamber of the heart. The pressure transducer produces a pressure signal indicative of right ventricular, left ventricular, or arterial pressure, depending upon the location of the pressure transducer.
- For the ST segment, the electrical signal can be obtained from a set of implanted or external electrodes. For dynamic heart activity, an accelerometric signal can be obtained from an accelerometer deployed within or near the heart. The accelerometer transduces heart contractions into one or more accelerometric signals. The pressure signal can be obtained from a pressure transducer deployed within the heart or vasculature. Alternately, the pressure sensor could be positioned around a blood vessel.
- The accelerometer can be disposed at the distal tip of an implanted lead that is deployed within a chamber of the heart. The pressure transducer can be realized by a cardiac pressure lead. A signal processing circuit can be used to detect drops in contractility during myocardial ischemia by comparing the accelerometric or pressure signal to a criterion such as a predetermined threshold.
- The invention correlates contractility changes derived from signals generated by a lead tip accelerometer or cardiac pressure lead with changes in the ST segment to increase the specificity of ischemia detection. In particular, the utilization of a lead tip accelerometer or pressure lead in conjunction with electrical detection permits differentiation between ST segment changes accompanied by changes in cardiac contractility and ST segment changes without significant changes in cardiac contractility. Changes in cardiac contractility derived from the accelerometer or pressure lead provide another indication of ischemic conditions, and confirm the indication provided by the ST segment.
- In one embodiment, the invention provides a method for detecting myocardial ischemia, the method comprising obtaining a first signal indicative of dynamic mechanical activity of a heart, obtaining a second signal indicative of electrical activity of the heart, and detecting myocardial ischemia based on both the first signal and the second signal. The invention also may provide computer-readable media carrying instructions for performing the method.
- In another embodiment, the invention provides a system for detecting myocardial ischemia, the system comprising a first sensor that generates a first signal indicative of dynamic mechanical activity of a heart, a second sensor that obtains a second signal indicative of electrical activity of the heart, and a processor that detects myocardial ischemia based on both the first signal and the second signal.
- In an added embodiment, the invention provides a method for detecting myocardial ischemia, the method comprising obtaining a first signal indicative of contractile activity of a heart, obtaining a second signal indicative of electrical activity of the heart, and detecting myocardial ischemia based on both the first signal and the second signal. The invention also may provide computer-readable media carrying instructions for performing the method.
- In a further embodiment, the invention provides a system for detecting myocardial ischemia, the system comprising means for generating a first signal indicative of contractile activity of a heart, means for obtaining a second signal indicative of electrical activity of the heart, and means for detecting myocardial ischemia based on both the first signal and the second signal.
- The invention is capable of providing a number of advantages. For example, correlation of changes in heart contractility with changes in the ST segment provide a more reliable indication of an ischemic event. In this manner, the invention is useful in increasing the specificity of ischemia detection, generally avoiding false indication of ischemic events due to axis shifts, electrical noise, cardiac pacing stimuli, high sinus or tachycardia rates, or other factors that undermine the effectiveness of a purely electrical detection technique. Also, the invention is capable of improving sensitivity to ischemic episodes by allowing the detection of ischemia when either the mechanical or the electrical signals are indicative of ischemia.
- In addition, the invention can be useful in quantifying a degree of ischemic tissue according to a degree of cardiac contractility and a degree of change in the ST segment. Moreover, the combination of electrical and mechanical monitoring of heart activity can aid in determining the location of ischemic tissue. In particular, both the electrical and mechanical signals can be monitored along multiple axes. The electrical signal may include multiple electrical signals obtained from different lead sets, whereas an accelerometer may be sensitive along two and perhaps three axes. Likewise, multiple accelerometers or pressure sensors can be used to achieve sensitivity along multiple axes.
- The above summary of the invention is not intended to describe every embodiment of the invention. The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
-
FIG. 1 is a diagram illustrating an exemplary implantable medical device in association with a heart. -
FIG. 2 is a diagram illustrating another exemplary implantable medical device in association with a heart. -
FIG. 3 is a side view illustrating an implantable lead suitable for incorporation of a lead-tip accelerometer. -
FIG. 4 is a cross-sectional side view of the lead shown inFIG. 3 . -
FIG. 5 is a block diagram illustrating a system for detection of ischemia. -
FIGS. 6A, 6B , and 6C are graphs illustrating the relationship between electrical activity and heart acceleration within a canine heart. -
FIGS. 7A, 7B , and 7C are graphs illustrating the relationship between electrical activity and heart acceleration within a canine heart during an episode of ischemia. -
FIG. 8 is another graph illustrating changes in heart acceleration in the presence of ischemia. -
FIG. 9 is a flow diagram illustrating a process for ischemia detection. -
FIG. 10 is a flow diagram illustrating another process for ischemia detection. -
FIG. 11 is a flow diagram illustrating a process for ischemia detection in greater detail. -
FIG. 1 is a diagram illustrating an implantable medical device (IMD) 10 in association with aheart 34.IMD 10 may be configured for both monitoring and therapy ofheart 34. For example,IMD 10 may include a pulse generator to deliver electrical stimulation toheart 34 for use in cardioversion or defibrillation. In accordance with the invention,IMD 10 obtains a signal indicative of dynamic mechanical activity ofheart 34, and an electrical signal indicative of electrical activity of the heart. - Using both signals, i.e., the electrical signal and the signal indicative of dynamic mechanical activity,
IMD 10 detects the existence of myocardial ischemia withinheart 34. When both signals reveal ischemic conditions,IMD 10 indicates an ischemic episode. The signal indicative of dynamic mechanical activity corroborates the electrical signal. - If ischemia is detected,
IMD 10 can be configured to deliver appropriate therapy to alleviate its effects. The therapy may include drug delivery, electrical stimulation, or both. In addition, according to some embodiments,IMD 10 may determine the location of ischemic tissue and the severity of the ischemic condition, providing more specific information that may be useful in selection of treatment. -
IMD 10 may be generally flat and thin to permit subcutaneous implantation within a human body, e.g., within upper thoracic regions or the lower abdominal region.IMD 10 may include a hermetically sealedhousing 14 having aconnector block assembly 12 that receives the proximal ends of one or more cardiac leads for connection to circuitry enclosed withinhousing 14. In the example ofFIG. 1 ,connector block assembly 12 receives a ventricularendocardial lead 28. - In some embodiments of the invention, ventricular
endocardial lead 28, or other leads, may include an accelerometer to obtain a heart acceleration signal or a pressure transducer to obtain a pressure signal. In other embodiments, a pressure signal can be obtained from outside a blood vessel, e.g., with the use of implantable blood vessel cuffs as described in U.S. Pat. Nos. 6,010,477 and 6,077,277 to Miesel et al. - Also, multiple accelerometers or pressure sensors can be used to achieve sensitivity along multiple axes. For instance, if a coronary artery providing oxygen to the left side of the heart is occluded, there may be a decrease in accelerometer—or pressure sensor-indicated contractility from a left-sided lead, but not necessarily from a lead in the right ventricle. This may be particularly the case for an accelerometer lead placed on the right ventricular free wall, which is not mechanically coupled to the left ventricle, as well as a lead placed on the ventricular septum. Accordingly, multiple sensors may be desirable for enhanced sensitivity.
- An accelerometer will be generally described herein for purposes of illustration. Ventricular
endocardial lead 28 may be, for example, a bipolar, two wire lead equipped to sense electrical signals. An accelerometer can be incorporated adjacent adistal tip 30 oflead 28, and thereby deployed withinheart 34. As will be described,housing 14 may enclose circuitry for use in analyzing the heart acceleration signal produced by the accelerometer, and electrical signals such as ECGs or EGMs obtained byIMD 10 to detect ischemia withinheart 34. - To facilitate detection of electrical activity within
heart 34,IMD 10 may include a plurality ofEGM sense electrodes EGM sense electrodes electrodes housing 12 ofIMD 10. - The sense electrode pairs can be used to obtain electrical signals along one or more sensing axes to formulate one or more EGM signals. The EGM signal obtained via
sense electrodes heart 34. The accelerometer provides an indication of the dynamic mechanical activity of the heart, which either reinforces or negates an indication of ischemia derived from a change in the electrical signal. - As an advantage, in addition to identification of ischemia, the heart acceleration signal can be used to measure other events in different frequency ranges. For example, the heart acceleration signal may be monitored from 0 to 0.5 Hz for the patient's posture or orientation, from 1 to 5 Hz for the patient's activity, e.g., exercise, and from 5 to 100 Hz for the patient's heart acceleration. The frequency range for analysis of heart acceleration is the range useful in identification of ischemia. Thus, the accelerometer may serve multiple purposes. For example, by analyzing the pertinent frequency bands, the accelerometer may be used to detect patient activity, patent orientation, and heart acceleration.
- As further shown in
FIG. 1 , a programmer/output device 44 with an antenna 46 can be provided for wireless communication withIMD 10.IMD 10 may include a telemetry circuit that transmits radio frequency messages, which may include indications of ischemia and other information to device 44.IMD 10 also may receive programming information via the telemetry circuit for modification of operational parameters within the IMD. - Device 44 also may include a display for graphic or textual presentation of information transmitted by
IMD 10, as well as a visible or audible annunciator that provides an indication of the detection of ischemia withinheart 34.IMD 10 also may be equipped with an alarm for notification of the patient in the event ischemia is detected. Also, device 44 may include a user input device, such as a keypad, by which a physician may modify operational parameters for use inprogramming IMD 10 for diagnosis or treatment. -
FIG. 2 is a diagram illustrating anotherIMD 48 in association with ahuman heart 34. In particular,IMD 48 may be configured to provide electrical stimuli toheart 34 for defibrillation.IMD 48 may generally conform to the defibrillation system described in the above-referenced U.S. Pat. No. 6,128,526. In the example ofFIG. 2 ,IMD 48 includes anouter housing 54 that functions as an electrode, along with a set ofelectrodes connector block 50. -
IMD 48 may include leads 60, 62 for deployment ofdefibrillation coil electrodes heart 34. Leads 60, 62 may include additional electrodes, such aselectrodes heart 34.Electrodes respective electrodes IMD 48. As in the example ofFIG. 1 , an accelerometer can be mounted in one ofleads -
FIG. 3 is a side view illustrating animplantable lead 76 equipped with a lead-tip accelerometer.Lead 76 may be configured for use as a diagnostic lead, therapeutic lead, or both, and may be incorporated with a variety of IMDs including those shown inFIGS. 1 and 2 . For example, lead 76 may carry sense electrodes, stimulation electrodes, or both. As shown inFIG. 3 , lead 76 may include adistal tip 78, afirst section 80, and asecond section 82. First andsection sections outer walls - One or more sense or stimulation electrodes may be formed along the longitudinal extent of
outer walls Distal tip 78 may include anelectrode 84, as well as a number of stabilizing tines (not shown inFIG. 3 ) for securingdistal tip member 78 in cardiac tissue upon deployment. In addition, lead 76 may include electrical conductors which may be coupled toelectrode 84 and an accelerometer assembly mounted withinsecond section 82. -
FIG. 4 is a cross-sectional side view oflead 76 shown inFIG. 3 .FIG. 4 showsfirst section 80,second section 82,distal tip 78,electrode 84. Stabilizing tines or other anchoring structure may be added todistal tip 78, if desired. In the example ofFIG. 4 , lead 76 includes anaccelerometer assembly 88 mounted withinsecond section 82 adjacentdistal tip 78.Accelerometer assembly 88 forms a capsule, and includes an accelerometer that may be fabricated using microelectromechanical systems (MEMS) technology, providing high tolerance and very small size. Advantageously,accelerometer assembly 88 may be used in a bipolar lead system, reducing accelerometer assembly size and increasing reliability. -
Lead 76 also includes conductors in the form of first and second conductivecoiled conductors Coiled conductors distal electrode 84 andaccelerometer assembly 88 to carry electrical current to and from the electrode and accelerometer assembly to a proximal end of the lead, which may be coupled to an IMD. For example, inner coiledconductor 90 may be coupled to interior components ofaccelerometer assembly 88 via afeedthrough assembly 86. Outercoiled conductor 92 may be coupled to the exterior housing ofaccelerometer assembly 88, which is electrically conductive and may be formed from titanium, and toelectrode 84. The accelerometer signal may be produced betweenconductors electrode 84 may be produced betweenconductor 92 and an electrode on the IMD housing or “can.”Distal tip 78,first section 80, andsecond section 82 are crimped together at crimp points indicated generally byreference numerals adhesive material 99 fills the void withinfeedthrough assembly 86. - The heart acceleration signal varies as a function of the contractile force of
heart 34. The contractile force is transduced byaccelerometer assembly 88 to produce an electrical heart acceleration signal that represents the contractility of the heart and, more generally, the dynamic mechanical activity of the heart. The contractile force ofheart 34 physically deforms the accelerometer inassembly 88 to change its electrical properties, and modulate the current passing through the accelerometer. Again, an indication of heart contractility can be obtained alternatively using a pressure transducer. -
Accelerometer assembly 88 can make use of conventional accelerometer technology and may take the form of a piezoelectric, piezoresistive, capacitive, inductive, or magnetic sensor that produces a change in an electrical property with changes in accelerometric force withinheart 34. The changes in the electrical property, e.g., resistance, capacitance, inductance, and the like, in turn produces changes in the electrical signal produced byaccelerometer assembly 88. - In the example of
FIG. 4 ,accelerometer assembly 88 is mounted at the tip or distal end oflead 76.Accelerometer assembly 88 could be mounted elsewhere withinlead 76, however, provided it can be properly positioned and oriented to detect accelerometric force produced by the contractile activity ofheart 34. In some embodiments,accelerometer assembly 88 may be formed to have either one, two, or three detection axes. In other words,accelerometer assembly 88 may be configured to detect accelerometric force extending in multiple directions as a result of the contractile force generated by different walls withinheart 34. - In this case,
accelerometer assembly 88 may be equipped with a multi-axis accelerometer or multiple accelerometers oriented orthogonally in relation to the respective axes, as well as multiple conductors for obtaining the heart acceleration signal as output from each respective accelerometer. As one example,accelerometer assembly 88 could include a single conductor line that carries current to multiple accelerometers, and two or more additional conductor lines that return current from each of the accelerometers to provide separate heart acceleration signal outputs for the different axes. Alternatively, each accelerometer may be coupled to the same conductor lines, and produce signals that are time-multiplexed to distinguish the output of each accelerometer. - Detection of heart acceleration along multiple axes may be useful in determining the location of ischemic tissue. If the heart acceleration signal along one axis is “normal,” i.e., not indicative of ischemia, whereas the heart acceleration signal along another axis indicates a possible episode of ischemia, the location of the ischemic tissue can be determined according to the orientation of the axis along which the pertinent accelerometer is aligned.
- In this manner, the ischemic condition can be treated, by intervention of a physician or in an automated manner, and targeted to an appropriate region of
heart 34. For example, based on the location of the ischemic tissue, electrical stimulation can be delivered to a selected stimulation electrode best suited for treatment of the affected location. - In addition, the amplitude, frequency, or pulse width of stimulating current can be controlled according to the affected location to achieve an optimum therapeutic effect. As a further alternative, determination of the location of ischemic tissue can be used to choose other types of therapy such as drug delivery, as well as types, dosages and durations of drug delivery. Also, the location information can be compared to location information recorded in the past to determine whether the ischemia is occurring in a new location or a location of prior ischemic episodes.
-
FIG. 5 is a block diagram illustrating asystem 100 for detection of ischemia. As shown inFIG. 5 ,system 100 may include alead selector circuit 102 that selects one or more lead pairs 104, asignal processor circuit 106, anaccelerometer 108, aprocessor 110,memory 112, atherapy control circuit 112, atherapy delivery system 114, and atelemetry device 116 with anantenna 118. Leadselector circuit 102 may be controlled byprocessor 110, and select lead pairs for acquisition of electrical signals oriented along multiple detection axes relative toheart 34. -
Processor 110 may take the form of a microprocessor, microcontroller, digital signal processor (DSP) or other programmable logic device. The electrical signals obtained via the lead pairs can be used to formulate an ECG or EGM for analysis of the PQRST complex and, in particular, the ST segment. Changes in the ST segment can be an indicator of ischemia. Analysis of the dynamic mechanical activity of the heart in combination with changes in the ST segment, according to the invention, can provide a more reliable indication of ischemia. -
Signal processor circuit 106 receives the output oflead selector circuit 102 and a heart acceleration signal from anaccelerometer 108, which may be deployed in a lead tip as described with reference toFIGS. 3 and 4 . In other embodiments,signal processor circuit 106 may receive a pressure signal from a pressure transducer. The output oflead selector circuit 102 may be three electrode pair signals, such as RV coil-can, RV ring-can, and SVC coil-can. In some embodiments, as discussed above,accelerometer 108 may produce multiple heart acceleration signals oriented along similar detection axes.Signal processor circuit 106 may include a number of sense amplifiers that amplify the ECG or EGM signals, as well as the heart acceleration signal. - In addition,
signal processor circuit 106 may include sampling and comparator circuitry for analysis of the electrical signals and heart acceleration signals relative to criteria such as average, peak-to-peak, or total amplitude thresholds. Alternatively,processor 110 may digitally sample the signals amplified bysignal processor circuit 106 and perform a software-based analysis of the digital signals. Thus,signal processor circuit 106 may include an analog-to-digital converter that converts the analog signals produced bylead selector circuit 102 andaccelerometer 108 into digital samples for analysis byprocessor 110.Processor 110 may provide the necessary control and clock signals for operation ofsignal processor circuit 106. - A
memory 112 is provided for storage of digital samples produced bysignal processor circuit 106 and intermediate data stored and retrieved byprocessor 110. For example,signal processor circuit 106 may include a number of buffers that hold digital samples for storage in memory. Although not illustrated inFIG. 5 for simplicity,processor 110,memory 112, andsignal processor 106 may communicate via a common data and instruction bus, as is well known in the art. The digital samples may be parameterized, insignal processor circuit 106 orprocessor 110, to produce values for comparison to a predetermined threshold. Again, the comparison may take place within discrete circuitry provided bysignal processor circuit 106 or via code executed byprocessor 110. The code may include instructions carried by a computer-readable medium accessible byprocessor 110, such asmemory 112 or other fixed or removable media devices associated with an external programmer/output device communicatively coupled to the processor viatelemetry device 116. - ECG, EGM, SEA or other electrical signals produced by
lead selector circuit 102 can be processed and parameterized to represent a variety of different values useful in the comparison. In one embodiment, the electrical signals may be processed to produce an amplitude value, such as an average, peak-to-peak, or total amplitude, for the ST segment of the PQRST complex. The ST segment is typically close in amplitude to the baseline of the ECG or EGM signal sensed between consecutive PQRST sequences. During episodes of myocardial ischemia, however, the ST segment amplitude may increase or decrease substantially. Thus, by comparing the amplitude of the ST segment to an amplitude threshold,processor 110 can identify a potential episode of ischemia. - In addition,
processor 110 may be configured to detect a location of the ischemic condition based on which one of the lead pairs produces an ST segment excursion above the amplitude threshold. In some embodiments, the location may be correlated with one of several acceleration signals obtained fromaccelerometer 108 for different sensing axes. - An average amplitude may be obtained and represented in a number of ways such as by computing the average of a series of samples over the period of time coincident with the ST segment. A peak-to-peak amplitude for each signal can be obtained by detection of maxima and minima of the ST segment and detection of maxima and minima of a heart acceleration signal over a duration of time that generally coincides with the ST segment. A total amplitude for each signal can be obtained by integrating the ST segment and integrating the acceleration signal over a duration of time that generally coincides with the ST segment. Also, because the change in the ST segment may be elevated or depressed during an ischemic episode, the ST segment parameter may rely on the absolute value of the change in the ST segment.
- Because the use of the ST segment as an indicator of ischemia can be unreliable, processor 110 (and/or signal processor circuit 106) is also configured to analyze the heart acceleration signal produced by
accelerometer 108. In particular,processor 110 compares a parameterized value representative of the heart acceleration signal, such as an average amplitude or integrated amplitude, at a time substantially coincident with the ST segment to a pertinent threshold. In this manner,system 100 is capable of correlating the ST segment and the heart acceleration signal for more reliable detection of ischemia. - By verifying whether the heart acceleration signal (or alternatively a pressure signal) also indicates ischemia,
processor 110 is able to disregard deviations in the ST segments due to conditions other than ischemia, e.g., due to changes in the overall PQRST complex caused by axis shifts, electrical noise, cardiac pacing stimuli, drugs, and high sinus or tachycardia rates that distort the PQRST complex. Consequently,system 100 is capable of reducing the number of false indications of ischemia, and increasing the reliability of the ST segment as an indicator of myocardial ischemia. - Based on deviation of the ST segment and the heart acceleration signal relative to the pertinent thresholds,
processor 110 also may quantify the severity of the ischemic condition. If the ST segment and the heart acceleration signal both satisfy the pertinent thresholds,processor 110 indicates an ischemic event, and may be programmed to effect therapeutic action. For example,processor 110 may generate a therapy control signal that causes atherapy control circuit 112 to request delivery of therapy from atherapy delivery system 114.Therapy delivery system 114 may take, for example, the form of a drug delivery system or electrical stimulation system such as a cardioversion or defibrillation circuit. -
Processor 110 also may indicate totherapy control circuit 112 the location of the ischemic tissue and the severity of the ischemic condition based on the accelerometer signal. Accordingly,therapy control circuit 112 may be configured to controltherapy delivery system 114 based on the indications provided byprocessor 110. For example,therapy control circuit 112 may select the type of therapy, e.g., drug delivery and/or electrical stimulation, the dosage, amplitude, and duration of the therapy, as well as the location for delivery of the therapy, based on the indications of location and severity provided byprocessor 110. -
Processor 110 also may control atelemetry device 116 to communicate an indication of the ischemic condition to an external device viaantenna 118. Thus, the indication may be a wireless, radio frequency message that indicates an ischemic condition and, in some embodiments, the location of the ischemic tissue and the severity of the ischemic condition. In addition, the IMD itself may have an audible alarm that notifies the patient when an ischemic episode is occurring. - The external device, which may be a programmer/output device, advises a physician or other attendant of the ischemic condition, e.g., via a display or a visible or audible alarm. Also, the ischemic events may be stored in memory in the external device, or within the IMD, for review by a physician. The components of
system 100, with the exception ofaccelerometer 108 and leads 104, may be housed in a common housing such as those shown inFIGS. 1 and 2 . Alternatively, portions ofsystem 100 may be housed separately. For example,therapy delivery system 114 could be provided in a separate housing, particularly where the therapy delivery system includes drug delivery capabilities. In this case,therapy control circuit 112 may interact withtherapy delivery system 114 via an electrical cable or wireless link. -
FIGS. 6A, 6B , and 6C are graphs illustrating an example relationship between electrical activity and heart acceleration within a canine heart. In particular,FIG. 6A shows an ECG signal, including the R-wave peak, ST segment and T-wave over a period of time.FIG. 6B shows the output of a pressure sensor positioned within the left ventricle, e.g., in a lead deployed within the ventricle, over the same period of time.FIG. 6C shows the output of an accelerometer positioned within the right ventricle, e.g., at the tip of a lead deployed within the ventricle, also over the same period of time. - The heart acceleration signal is characterized by a
section 120 that generally coincides in time with the ST segment of the ECG signal. Similarly, the pressure signal has asection 121 that coincides with the ST segment. In this example,sections -
FIGS. 6A and 6C also illustrate example amplitude thresholds T1 and T2. The thresholds may be used in analysis of the ST segment amplitude and heart acceleration signal amplitude, respectively. A similar threshold can be used for the pressure signal. The thresholds may reflect an average amplitude over the duration of the ST segment or a peak-to-peak amplitude. As an alternative, total amplitudes obtained, e.g., by integration of the heart acceleration signal, could be used for comparison to total amplitude thresholds. In the example ofFIGS. 6A-6C , thresholds T1 and T2 represent peak-to-peak amplitude thresholds for comparison to the maxima and minima of the ST segment and heart acceleration signal, respectively. -
FIGS. 7A, 7B , and 7C are graphs illustrating an example relationship between electrical activity and heart acceleration within a canine heart during an episode of ischemia. As shown inFIG. 7A , the ST segment of an ECG or EGM signal may show a significant increase when the heart tissue becomes ischemic. In comparison toFIG. 6A , for example, the amplitude of the ST segment inFIG. 7A is markedly increased, and exceeds the threshold T1, which may be specified by a physician for identification of ischemic conditions. InFIG. 7B , the amplitude of the pressure signal is decreased relative to that shown inFIG. 6B . - As shown in
FIG. 7C , the heart acceleration signal also shows the effects of ischemia. Specifically, in a case of ischemia, thesection 120 of the heart acceleration signal that coincides with the ST segment is markedly decreased in amplitude relative toFIG. 6C . In this example,section 120 has a peak-to-peak amplitude that is less than the threshold T2. Thus, when the amplitude of the ST segment exceeds threshold T1 and the amplitude of the heart acceleration signal drops below threshold T2, an episode of ischemia can be more reliably indicated in accordance with the invention. - Again, the amplitudes of the ST segment and heart acceleration signal, as well as the thresholds T1 and T2, may be peak-to-peak, average, or total amplitudes, or any other parameter deemed reliable in detection of ischemia. The basic technique simply involves analysis of both the ST segment and the heart acceleration signal in a correlative manner to reduce the possibility that changes in the ST segment are due to factors other than ischemia. This enables a reduction in the number of false indications.
-
FIG. 8 is another graph illustrating changes in heart acceleration in the presence of ischemia. In particular,FIG. 8 illustrates changes in the heart acceleration signal 122 during an experiment in which ischemia is induced in a canine heart. The left axis of the graph shows the accelerometer peak-to-peak signal, measured in gravitational gs. The bottom axis shows the progression of time. The right axis shows anischemia parameter 124. Theischemia parameter 124 can be derived from, for example, an electrical signal such as the ST segment of an ECG or EGM signal. In particular,ischemia parameter 124 may represent the ST segment change as a percentage of the R-wave amplitude. - As shown in
FIG. 8 , following adobutamine infusion 123, the heart acceleration signal 122 peaks sharply, as the dobutamine induces a forceful contraction in the heart. Later, the heart is subjected to balloon occlusion to intentionally limit the flow of blood, and thereby induce ischemia. At that time, the ischemia parameter peaks sharply, as indicated byreference numeral 125, whereas the heart acceleration signal 122 drops noticeably, as indicated byreference numeral 128. When the balloon occlusion is again applied, as indicated byreference numeral 126, the heart acceleration signal 122 again drops while the ischemia parameter peaks. The vertical dashed lines inFIG. 8 denote the duration of the dobutamine infusion, first balloon occlusion, and second balloon occlusion. -
FIG. 9 is a flow diagram illustrating a process for ischemia detection. In general, the process may include obtaining an electrical signal such as an ECG or EGM signal (130) and applying a first criterion to the signal (132). For example, the first criterion may be an amplitude threshold that is compared to an amplitude parameter of the electrical signal, such as an average, peak-to-peak or total amplitude of the ST segment of the electrical signal. If the first criterion is not satisfied, the process returns to evaluation of the electrical signal (130). - If the first criterion is satisfied (134), the technique involves obtaining an accelerometer signal, i.e., a heart acceleration signal (136), and applying a second criterion to the accelerometer signal (138). The second criterion, like the first criterion, may be an amplitude threshold that is compared to an amplitude parameter of the heart acceleration signal, such as an average, peak-to-peak, or total amplitude in a region that temporally coincides with the ST segment of the electrical signal.
- If the second criterion is not satisfied, the process returns to evaluation of the electrical signal (130). If the second criterion is satisfied (140), however, the process indicates an ischemic episode (142). In some embodiments, the process may respond to an indication of ischemia by delivering therapy to the patient (144). For example, the process may involve drug delivery or electrical stimulation. The drug delivery and electrical stimulation may be delivered by an implantable medical device, including one that is integrated with ischemia detection circuitry. Alternatively, drug delivery and electrical stimulation may be administered to the patient externally.
-
FIG. 10 is a flow diagram illustrating another process for ischemia detection. The process ofFIG. 10 is similar to that ofFIG. 9 , but illustrates the acquisition of multiple electrical signals for different axes to facilitate determination of the location of ischemic tissue. In particular, the process may involve obtaining multiple ECG signals (144), applying a first criterion to the signals (146), and determining whether the criterion is satisfied for any of the signals (148). If so, the process identifies the electrical signals that satisfy the criterion (150), and then obtains the accelerometer signal (152). - Upon application of a second criterion to the accelerometer signal (154), and satisfaction of that criterion (156), the process indicates an episode of ischemia along with an indication of the location of ischemic tissue based on which of the electrical signals satisfied the first criterion (158), i.e., which of the electrical signals showed a change in the ST segment indicative of ischemia. On this basis, the process may further involve delivery of therapy (160) and, in some embodiments, delivery of therapy to a particular location within the heart, or in a form selected for a particular location.
- Determination of the location of ischemic tissue within the heart also can be aided by obtaining multiple heart acceleration signals along multiple axes. Like the electrical signals, the heart acceleration signals may indicate ischemia along one axis but not necessarily the others, enabling isolation of more specific region of ischemia within the heart. As with the electrical signals, this may aid in selection of the type, level, and focus of the therapy delivered to the patient.
-
FIG. 11 is a flow diagram illustrating a process for ischemia detection in greater detail. As shown inFIG. 11 , the process may involve analysis of an electrical signal such as an ECG or EGM signal to identify the ST segment (162). The ST segment may be parameterized (164), e.g., as a peak-to-peak amplitude, average amplitude, or total amplitude, and compared to an amplitude threshold T1 (166). If the ST segment amplitude exceeds the threshold T1, there is a potential ischemic condition. - To more reliably confirm the ischemia, the process involves obtaining an accelerometer signal (168), parameterizing the accelerometer signal (170), and comparing it to an amplitude threshold T2 (172). If the accelerometer signal amplitude drops below the threshold T2 (172), a contractility change is confirmed in addition to the increase in the ST segment, providing a more reliable indication of ischemia. On this basis, the process indicates an ischemic condition (174) and may use the indication as the basis for delivery of therapy (176) to the patient.
- Amplitude thresholds are described herein for purposes of example, and are not to be read as limiting of the invention as broadly claimed. Other signal parameters may be appropriate for evaluation in identifying ischemia. Also, it is noted that exceeding a given threshold may refer to a change that results in an increase above or below a certain level, for example, as described with reference to the graphs of
FIGS. 6, 7 , and 8. Specifically, in some cases, ischemia may be indicated by an increase in the ST segment amplitude and a decrease in the heart acceleration signal at the time of the ST segment. Also, in some embodiments, the electrical and acceleration signals could be combined into a single parameterized value that is compared to a single threshold value to determine whether an ischemic episode is indicated. - The use of a signal indicative of dynamic mechanical heart activity to confirm an episode of ischemia indicated by the ST segment of an electrical signal can provide a number of advantages including more reliable indication of ischemia, avoidance of false indications and unnecessary administration of treatment. In addition, the heart acceleration signal may be useful, alone or in combination with the electrical signal, in more reliably quantifying the contractile function of the heart, and hence the degree of ischemia, providing a standard for the type or amount of therapy delivered to the patient.
- In addition, a multi-dimensional heart acceleration signal, alone or in combination with the electrical signal, can be used to better identify the location of ischemic tissue. In effect, the use of a multi-axial accelerometer in a lead tip can detect axis shift due to postural changes and add sensitivity to the ischemia detection. The multi-axial accelerometer signals can be combined in a logical OR fashion to increase sensitivity to ischemia, or combined in a logical AND fashion to increase specificity, i.e., in terms of the location of the ischemic tissue. In addition, relative changes in the orthogonal accelerometer signals can be used to more narrowly identify the location of ischemic tissue.
- Various embodiments of the invention have been described. Alternative embodiments are conceivable. Rather than an accelerometer, for example, other sensors such as the pressure transducer described herein may be employed to obtain a signal indicative of cardiac contractility. Additionally, the maximum value of the first derivative of the pressure signal, often called the maximum DP/DT, can be used to assess the cardiac contractility and be used a signal indicative of ischemia. In particular, a blood pressure or velocity transducer may provide a signal useful in deriving a measure of cardiac contractility. These and other embodiments are within the scope of the following claims.
Claims (20)
1. A system for detecting myocardial ischemia, the system comprising:
means for generating a first signal indicative of contractile activity of a heart;
means for obtaining a second signal indicative of electrical activity of the heart; and
means for detecting myocardial ischemia based on both the first signal and the second signal.
2. A system according to claim 1 , further comprising means for controlling, subsequent to when myocardial ischemia is detected, delivering a therapy to alleviate effects of the ischemia within the heart.
3. A system according to claim 1 , wherein the therapy includes at least one of a drug delivery therapy, an electrical stimulation therapy, a combination of the drug delivery therapy and the electrical stimulation therapy.
4. A system according to claim 1 , wherein the means for generating the first signal includes an implanted accelerometer and the first signal comprises a heart acceleration signal.
5. A system according to claim 4 , wherein the accelerometer mechanically couples to a distal portion of a lead adapted to be implantable one of within and on an exterior portion of the heart.
6. A system according to claim 1 , wherein the means for obtaining the second signal indicative of electrical activity of the heart includes a subcutaneous electrode array (SEA).
7. A system according to claim 6 , wherein the system further comprises a subcutaneous ischemia monitoring circuit means disposed within a substantially hermetic housing in electrical communication with said SEA.
8. A system according to claim 1 , wherein the means for obtaining the second signal indicative of electrical activity of the heart includes at least one endocardial electrode disposed within a chamber or vasculature of the heart.
9. A system according to claim 1 , wherein the means for obtaining the second signal indicative of electrical activity of the heart includes at least one externally mounted electrode adapted to be coupled to a portion of epidermis of a subject.
10. A computer-readable medium containing instructions to produce a technical effect via at least one computer processor, comprising:
obtaining a first signal indicative of dynamic mechanical activity of a heart;
obtaining a second signal indicative of electrical activity of the heart; and
detecting a relative degree of an episode of myocardial ischemia based at least in part on both the first signal and the second signal.
11. A computer computer-readable medium according to claim 10 , wherein the first signal is derived from one of an implanted pressure transducer, an accelerometer, a velocity sensing apparatus.
12. A computer-readable medium according to claim 10 , wherein the first signal relates to one of a right ventricular contractile activity and a left ventricular contractile activity.
13. A computer-readable medium according to claim 12 , wherein the right ventricular contractile activity is provided from an endocardial location.
14. A computer-readable medium according to claim 12 , wherein the left ventricular contractile activity is provided from one of an epicardial location, a pericardial location, a location within a portion of a great vein or coronary sinus.
15. A computer-readable medium according to claim 12 , wherein the relative degree of the episode of myocardial ischemia is determined along at least a plurality of axes of one of said first signal and said second signal.
16. A computer-readable medium according to claim 11 , wherein the accelerometer mechanically couples to a distal portion of a lead adapted to be implantable one of: within a chamber of the heart, on an exterior portion of the heart, within a portion of vasculature of the heart.
17. A computer-readable medium according to claim 10 , wherein obtaining the second signal indicative of electrical activity of the heart includes a signal derived from a subcutaneous electrode array (SEA).
18. A computer-readable medium according to claim 17 , further comprising a subcutaneous ischemia monitoring circuit means disposed within a substantially hermetic housing in electrical communication with said SEA.
19. A computer-readable medium according to claim 10 , wherein obtaining the second signal indicative of electrical activity of the heart includes at least one endocardial electrode disposed within a chamber or a portion of vasculature of the heart.
20. A computer-readable medium according to claim 10 , wherein obtaining the second signal indicative of electrical activity of the heart includes at least one externally mounted electrode adapted to be coupled to a portion of epidermis of a subject.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/215,710 US20060009811A1 (en) | 2001-08-30 | 2005-08-30 | Ischemia detection |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/945,179 US6937899B2 (en) | 2001-08-30 | 2001-08-30 | Ischemia detection |
US11/215,710 US20060009811A1 (en) | 2001-08-30 | 2005-08-30 | Ischemia detection |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/945,179 Continuation US6937899B2 (en) | 2001-08-30 | 2001-08-30 | Ischemia detection |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060009811A1 true US20060009811A1 (en) | 2006-01-12 |
Family
ID=25482753
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/945,179 Expired - Lifetime US6937899B2 (en) | 2001-08-30 | 2001-08-30 | Ischemia detection |
US11/215,710 Abandoned US20060009811A1 (en) | 2001-08-30 | 2005-08-30 | Ischemia detection |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/945,179 Expired - Lifetime US6937899B2 (en) | 2001-08-30 | 2001-08-30 | Ischemia detection |
Country Status (2)
Country | Link |
---|---|
US (2) | US6937899B2 (en) |
WO (1) | WO2003020366A1 (en) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070054871A1 (en) * | 2005-09-06 | 2007-03-08 | Pastore Joseph M | Method and apparatus for device controlled gene expression for cardiac protection |
US20070150015A1 (en) * | 2005-12-23 | 2007-06-28 | Yi Zhang | Implantable cardiac device with ischemia response capability |
US20070299356A1 (en) * | 2006-06-27 | 2007-12-27 | Ramesh Wariar | Detection of myocardial ischemia from the time sequence of implanted sensor measurements |
US20080082135A1 (en) * | 2006-10-02 | 2008-04-03 | Cardiac Pacemakers, Inc. | Method and apparatus for identification of ischemic/infarcted regions and therapy optimization |
US20080081354A1 (en) * | 2006-10-02 | 2008-04-03 | Cardiac Pacemakers, Inc. | Devices, vectors and methods for inducible ischemia cardioprotection |
US20080091138A1 (en) * | 2003-08-21 | 2008-04-17 | Cardiac Pacemakers, Inc. | Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure |
US20080177156A1 (en) * | 2007-01-19 | 2008-07-24 | Cardiac Pacemakers, Inc. | Ischemia detection using pressure sensor |
US20080177194A1 (en) * | 2007-01-19 | 2008-07-24 | Cardiac Pacemakers, Inc. | Heart attack detector |
US20080188763A1 (en) * | 2006-03-01 | 2008-08-07 | Michael Sasha John | System and methods for sliding-scale cardiac event detection |
WO2009029943A1 (en) * | 2007-08-31 | 2009-03-05 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Implantable device, system including same, and method utilizing same |
US20090099467A1 (en) * | 2007-10-15 | 2009-04-16 | Pacesetter, Inc. | Method and system for tracking quality of life in patients with angina |
US20100016916A1 (en) * | 2008-07-16 | 2010-01-21 | Shantha Arcot-Krishnamurthy | Apparatus and methods for treatment of atherosclerosis and infarction |
US20100016913A1 (en) * | 2008-07-16 | 2010-01-21 | Shantha Arcot-Krishnamurthy | Intermittent pacing therapy for angina and disease prevention |
US20100030034A1 (en) * | 2008-07-31 | 2010-02-04 | Schulhauser Randal C | Apparatus and Method for Detecting Cardiac Events |
US20100081948A1 (en) * | 2004-06-18 | 2010-04-01 | Pastore Joseph M | Method and apparatus for localizing myocardial infarction during catheterization |
US20100114231A1 (en) * | 2008-11-05 | 2010-05-06 | Pacesetter, Inc. | Methods and systems to monitor ischemia |
US7725171B1 (en) | 2007-08-31 | 2010-05-25 | Pacesetter, Inc. | System and method for tracking ST shift data utilizing histograms |
US7751882B1 (en) * | 2005-12-21 | 2010-07-06 | Pacesetter, Inc. | Method and system for determining lead position for optimized cardiac resynchronization therapy hemodynamics |
US20100312130A1 (en) * | 2006-06-27 | 2010-12-09 | Yi Zhang | Graded response to myocardial ischemia |
US7865232B1 (en) | 2007-08-07 | 2011-01-04 | Pacesetter, Inc. | Method and system for automatically calibrating ischemia detection parameters |
US7930017B1 (en) | 2007-05-25 | 2011-04-19 | Pacesetter, Inc. | Method and system for trending variation in coronary burden across multiple heart rate ranges |
US7949388B1 (en) | 2007-03-16 | 2011-05-24 | Pacesetter, Inc. | Methods and systems to characterize ST segment variation over time |
US20130053907A1 (en) * | 2011-08-23 | 2013-02-28 | Jens Kirchner | Comparison of right-ventricular and left-ventricular contraction using an accelerometer in an artery close to the heart |
US8467862B2 (en) | 2010-03-30 | 2013-06-18 | Pacesetter, Inc. | Systems and methods related to ST segment monitoring by an implantable medical device |
Families Citing this family (190)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7097618B1 (en) * | 2003-03-12 | 2006-08-29 | Transoma Medical, Inc. | Devices and methods for detecting and treating inadequate tissue perfusion |
US20050154370A1 (en) * | 1999-10-29 | 2005-07-14 | Medtronic, Inc. | Methods and systems for providing therapies into the pericardial space |
US7369890B2 (en) * | 2000-11-02 | 2008-05-06 | Cardiac Pacemakers, Inc. | Technique for discriminating between coordinated and uncoordinated cardiac rhythms |
US7340303B2 (en) * | 2001-09-25 | 2008-03-04 | Cardiac Pacemakers, Inc. | Evoked response sensing for ischemia detection |
US7113823B2 (en) | 2001-10-26 | 2006-09-26 | Cardiac Pacemakers, Inc. | Morphology-based optimization of cardiac resynchronization therapy |
US7286876B2 (en) | 2001-10-26 | 2007-10-23 | Cardiac Pacemakers, Inc. | Template-based capture verification for multi-site pacing |
US7181268B2 (en) * | 2001-12-03 | 2007-02-20 | Medtronic, Inc. | Ischemia detection |
US6865420B1 (en) | 2002-01-14 | 2005-03-08 | Pacesetter, Inc. | Cardiac stimulation device for optimizing cardiac output with myocardial ischemia protection |
US20040122487A1 (en) | 2002-12-18 | 2004-06-24 | John Hatlestad | Advanced patient management with composite parameter indices |
US20040122294A1 (en) | 2002-12-18 | 2004-06-24 | John Hatlestad | Advanced patient management with environmental data |
US8391989B2 (en) | 2002-12-18 | 2013-03-05 | Cardiac Pacemakers, Inc. | Advanced patient management for defining, identifying and using predetermined health-related events |
US8043213B2 (en) | 2002-12-18 | 2011-10-25 | Cardiac Pacemakers, Inc. | Advanced patient management for triaging health-related data using color codes |
US7043305B2 (en) | 2002-03-06 | 2006-05-09 | Cardiac Pacemakers, Inc. | Method and apparatus for establishing context among events and optimizing implanted medical device performance |
US7983759B2 (en) | 2002-12-18 | 2011-07-19 | Cardiac Pacemakers, Inc. | Advanced patient management for reporting multiple health-related parameters |
US7039462B2 (en) * | 2002-06-14 | 2006-05-02 | Cardiac Pacemakers, Inc. | Method and apparatus for detecting oscillations in cardiac rhythm |
US7089055B2 (en) * | 2002-06-28 | 2006-08-08 | Cardiac Pacemakers, Inc. | Method and apparatus for delivering pre-shock defibrillation therapy |
US8509897B2 (en) | 2002-09-19 | 2013-08-13 | Cardiac Pacemakers, Inc. | Morphology-based diagnostic monitoring of electrograms by implantable cardiac device |
US7072711B2 (en) | 2002-11-12 | 2006-07-04 | Cardiac Pacemakers, Inc. | Implantable device for delivering cardiac drug therapy |
US7066891B2 (en) * | 2002-12-20 | 2006-06-27 | Medtronic, Inc. | Method and apparatus for gauging severity of myocardial ischemic episodes |
US7378955B2 (en) * | 2003-01-03 | 2008-05-27 | Cardiac Pacemakers, Inc. | System and method for correlating biometric trends with a related temporal event |
US7529583B1 (en) * | 2003-01-15 | 2009-05-05 | Transoma Medical, Inc. | Therapeutic device and method using feedback from implantable pressure sensor |
US7445605B2 (en) | 2003-01-31 | 2008-11-04 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of apex motion for monitoring cardiac dysfunction |
US7130681B2 (en) | 2003-05-09 | 2006-10-31 | Medtronic, Inc. | Use of accelerometer signal to augment ventricular arrhythmia detection |
US7218960B1 (en) | 2003-06-24 | 2007-05-15 | Pacesetter, Inc. | System and method for detecting cardiac ischemia based on T-waves using an implantable medical device |
US7225015B1 (en) * | 2003-06-24 | 2007-05-29 | Pacesetter, Inc. | System and method for detecting cardiac ischemia based on T-waves using an implantable medical device |
US7274959B1 (en) | 2003-06-24 | 2007-09-25 | Pacesetter, Inc. | System and method for detecting cardiac ischemia using an implantable medical device |
US8396565B2 (en) | 2003-09-15 | 2013-03-12 | Medtronic, Inc. | Automatic therapy adjustments |
US20050137626A1 (en) * | 2003-12-19 | 2005-06-23 | Pastore Joseph M. | Drug delivery system and method employing external drug delivery device in conjunction with computer network |
US7412287B2 (en) | 2003-12-22 | 2008-08-12 | Cardiac Pacemakers, Inc. | Automatic sensing vector selection for morphology-based capture verification |
US7668594B2 (en) | 2005-08-19 | 2010-02-23 | Cardiac Pacemakers, Inc. | Method and apparatus for delivering chronic and post-ischemia cardiac therapies |
US7107096B2 (en) * | 2004-01-28 | 2006-09-12 | Angel Medical Systems, Inc. | System for patient alerting associated with a cardiac event |
US7232435B2 (en) * | 2004-02-06 | 2007-06-19 | Medtronic, Inc. | Delivery of a sympatholytic cardiovascular agent to the central nervous system to counter heart failure and pathologies associated with heart failure |
US7181269B1 (en) | 2004-04-12 | 2007-02-20 | Pacesetter, Inc. | Implantable device that diagnoses ischemia and myocardial infarction and method |
US7567841B2 (en) * | 2004-08-20 | 2009-07-28 | Cardiac Pacemakers, Inc. | Method and apparatus for delivering combined electrical and drug therapies |
US7295874B2 (en) * | 2005-01-06 | 2007-11-13 | Cardiac Pacemakers, Inc. | Intermittent stress augmentation pacing for cardioprotective effect |
US7662104B2 (en) | 2005-01-18 | 2010-02-16 | Cardiac Pacemakers, Inc. | Method for correction of posture dependence on heart sounds |
US7470233B2 (en) * | 2005-01-26 | 2008-12-30 | Medtronic, Inc. | Method and apparatus for muscle function measurement |
US7447543B2 (en) * | 2005-02-15 | 2008-11-04 | Regents Of The University Of Minnesota | Pathology assessment with impedance measurements using convergent bioelectric lead fields |
US7555340B2 (en) | 2005-04-01 | 2009-06-30 | Cardiac Pacemakers, Inc. | Electrogram morphology-based CRT optimization |
US8412314B2 (en) * | 2005-04-25 | 2013-04-02 | Charles Olson | Location and displaying an ischemic region for ECG diagnostics |
US7751874B2 (en) * | 2005-04-25 | 2010-07-06 | Charles Olson | Display for ECG diagnostics |
US7366568B2 (en) | 2005-05-06 | 2008-04-29 | Cardiac Pacemakers, Inc. | Controlled delivery of intermittent stress augmentation pacing for cardioprotective effect |
US7894896B2 (en) * | 2005-05-13 | 2011-02-22 | Cardiac Pacemakers, Inc. | Method and apparatus for initiating and delivering cardiac protection pacing |
US7917210B2 (en) | 2005-05-13 | 2011-03-29 | Cardiac Pacemakers, Inc. | Method and apparatus for cardiac protection pacing |
US20060259088A1 (en) * | 2005-05-13 | 2006-11-16 | Pastore Joseph M | Method and apparatus for delivering pacing pulses using a coronary stent |
US7922669B2 (en) | 2005-06-08 | 2011-04-12 | Cardiac Pacemakers, Inc. | Ischemia detection using a heart sound sensor |
US7742815B2 (en) * | 2005-09-09 | 2010-06-22 | Cardiac Pacemakers, Inc. | Using implanted sensors for feedback control of implanted medical devices |
US20070073352A1 (en) * | 2005-09-28 | 2007-03-29 | Euler David E | Method and apparatus for regulating a cardiac stimulation therapy |
US8108034B2 (en) | 2005-11-28 | 2012-01-31 | Cardiac Pacemakers, Inc. | Systems and methods for valvular regurgitation detection |
US7957809B2 (en) | 2005-12-02 | 2011-06-07 | Medtronic, Inc. | Closed-loop therapy adjustment |
US20070142727A1 (en) * | 2005-12-15 | 2007-06-21 | Cardiac Pacemakers, Inc. | System and method for analyzing cardiovascular pressure measurements made within a human body |
US7885710B2 (en) * | 2005-12-23 | 2011-02-08 | Cardiac Pacemakers, Inc. | Method and apparatus for tissue protection against ischemia using remote conditioning |
US7567836B2 (en) * | 2006-01-30 | 2009-07-28 | Cardiac Pacemakers, Inc. | ECG signal power vector detection of ischemia or infarction |
US7418868B1 (en) | 2006-02-21 | 2008-09-02 | Pacesetter, Inc. | Pressure sensor and method of fabricating such a module |
US7848808B2 (en) * | 2006-02-28 | 2010-12-07 | Medtronic, Inc. | System and method for delivery of cardiac pacing in a medical device in response to ischemia |
US20070219454A1 (en) * | 2006-03-02 | 2007-09-20 | Guzzetta J J | ECG method and system for optimal cardiac disease detection |
US7780606B2 (en) * | 2006-03-29 | 2010-08-24 | Cardiac Pacemakers, Inc. | Hemodynamic stability assessment based on heart sounds |
US7610086B1 (en) | 2006-03-31 | 2009-10-27 | Pacesetter, Inc. | System and method for detecting cardiac ischemia in real-time using a pattern classifier implemented within an implanted medical device |
US7806833B2 (en) * | 2006-04-27 | 2010-10-05 | Hd Medical Group Limited | Systems and methods for analysis and display of heart sounds |
US7648464B1 (en) | 2006-07-19 | 2010-01-19 | Pacesetter, Inc. | Detecting ischemia using an implantable cardiac device based on morphology of cardiac pressure signal |
US7955268B2 (en) * | 2006-07-21 | 2011-06-07 | Cardiac Pacemakers, Inc. | Multiple sensor deployment |
US20080154144A1 (en) * | 2006-08-08 | 2008-06-26 | Kamil Unver | Systems and methods for cardiac contractility analysis |
US7640058B2 (en) * | 2006-09-29 | 2009-12-29 | Biotronik Crm Patent Ag | Biventricular heart stimulator |
US7736319B2 (en) * | 2007-01-19 | 2010-06-15 | Cardiac Pacemakers, Inc. | Ischemia detection using heart sound timing |
US8798723B2 (en) * | 2007-01-31 | 2014-08-05 | Medtronic, Inc. | System and method for ischemia classification with implantable medical device |
US7894884B2 (en) * | 2007-01-31 | 2011-02-22 | Medtronic, Inc. | System and method for ischemia classification with implantable medical device |
US7846104B2 (en) * | 2007-02-08 | 2010-12-07 | Heart Force Medical Inc. | Monitoring physiological condition and detecting abnormalities |
US8615296B2 (en) | 2007-03-06 | 2013-12-24 | Cardiac Pacemakers, Inc. | Method and apparatus for closed-loop intermittent cardiac stress augmentation pacing |
EP2254660A1 (en) | 2008-01-29 | 2010-12-01 | Cardiac Pacemakers, Inc. | Configurable intermittent pacing therapy |
JP5211177B2 (en) * | 2008-02-11 | 2013-06-12 | カーディアック ペースメイカーズ, インコーポレイテッド | Hemodynamic monitoring method for rhythm discrimination in the heart |
WO2009102640A1 (en) * | 2008-02-12 | 2009-08-20 | Cardiac Pacemakers, Inc. | Systems and methods for controlling wireless signal transfers between ultrasound-enabled medical devices |
US8140155B2 (en) | 2008-03-11 | 2012-03-20 | Cardiac Pacemakers, Inc. | Intermittent pacing therapy delivery statistics |
US8483826B2 (en) | 2008-03-17 | 2013-07-09 | Cardiac Pacemakers, Inc. | Deactivation of intermittent pacing therapy |
US8755901B2 (en) | 2008-07-11 | 2014-06-17 | Medtronic, Inc. | Patient assignment of therapy parameter to posture state |
US8708934B2 (en) | 2008-07-11 | 2014-04-29 | Medtronic, Inc. | Reorientation of patient posture states for posture-responsive therapy |
US8323218B2 (en) | 2008-07-11 | 2012-12-04 | Medtronic, Inc. | Generation of proportional posture information over multiple time intervals |
US9327129B2 (en) | 2008-07-11 | 2016-05-03 | Medtronic, Inc. | Blended posture state classification and therapy delivery |
US8401666B2 (en) | 2008-07-11 | 2013-03-19 | Medtronic, Inc. | Modification profiles for posture-responsive therapy |
US8583252B2 (en) | 2008-07-11 | 2013-11-12 | Medtronic, Inc. | Patient interaction with posture-responsive therapy |
US9050471B2 (en) | 2008-07-11 | 2015-06-09 | Medtronic, Inc. | Posture state display on medical device user interface |
US8150531B2 (en) | 2008-07-11 | 2012-04-03 | Medtronic, Inc. | Associating therapy adjustments with patient posture states |
US8504150B2 (en) | 2008-07-11 | 2013-08-06 | Medtronic, Inc. | Associating therapy adjustments with posture states using a stability timer |
US8712509B2 (en) * | 2008-07-25 | 2014-04-29 | Medtronic, Inc. | Virtual physician acute myocardial infarction detection system and method |
US8280517B2 (en) | 2008-09-19 | 2012-10-02 | Medtronic, Inc. | Automatic validation techniques for validating operation of medical devices |
JP5465252B2 (en) * | 2008-10-10 | 2014-04-09 | カーディアック ペースメイカーズ, インコーポレイテッド | System and method for determining cardiac output using pulmonary artery pressure measurements |
US9301698B2 (en) * | 2008-10-31 | 2016-04-05 | Medtronic, Inc. | Method and apparatus to detect ischemia with a pressure sensor |
US9795442B2 (en) | 2008-11-11 | 2017-10-24 | Shifamed Holdings, Llc | Ablation catheters |
US8632470B2 (en) * | 2008-11-19 | 2014-01-21 | Cardiac Pacemakers, Inc. | Assessment of pulmonary vascular resistance via pulmonary artery pressure |
US8369921B2 (en) | 2008-12-31 | 2013-02-05 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Accelerometer-based contact sensing assembly and system |
US9327070B2 (en) | 2009-04-30 | 2016-05-03 | Medtronic, Inc. | Medical device therapy based on posture and timing |
US8175720B2 (en) | 2009-04-30 | 2012-05-08 | Medtronic, Inc. | Posture-responsive therapy control based on patient input |
US9026223B2 (en) | 2009-04-30 | 2015-05-05 | Medtronic, Inc. | Therapy system including multiple posture sensors |
US8983600B2 (en) | 2009-05-15 | 2015-03-17 | Cardiac Pacemakers, Inc. | Method and apparatus for safety control during cardiac pacing mode transition |
US8958873B2 (en) | 2009-05-28 | 2015-02-17 | Cardiac Pacemakers, Inc. | Method and apparatus for safe and efficient delivery of cardiac stress augmentation pacing |
US20100324378A1 (en) * | 2009-06-17 | 2010-12-23 | Tran Binh C | Physiologic signal monitoring using ultrasound signals from implanted devices |
US20110028856A1 (en) * | 2009-07-29 | 2011-02-03 | Siemens Medical Solutions Usa, Inc. | System for Heart Performance Characterization and Abnormality Detection |
US8812104B2 (en) | 2009-09-23 | 2014-08-19 | Cardiac Pacemakers, Inc. | Method and apparatus for automated control of pacing post-conditioning |
US8917272B2 (en) * | 2009-09-30 | 2014-12-23 | Mckesson Financial Holdings | Methods, apparatuses, and computer program products for facilitating visualization and analysis of medical data |
US8412326B2 (en) | 2009-10-30 | 2013-04-02 | Cardiac Pacemakers, Inc. | Pacemaker with vagal surge monitoring and response |
US9357949B2 (en) | 2010-01-08 | 2016-06-07 | Medtronic, Inc. | User interface that displays medical therapy and posture data |
US9149210B2 (en) | 2010-01-08 | 2015-10-06 | Medtronic, Inc. | Automated calibration of posture state classification for a medical device |
US9956418B2 (en) | 2010-01-08 | 2018-05-01 | Medtronic, Inc. | Graphical manipulation of posture zones for posture-responsive therapy |
US8579834B2 (en) | 2010-01-08 | 2013-11-12 | Medtronic, Inc. | Display of detected patient posture state |
US9566441B2 (en) | 2010-04-30 | 2017-02-14 | Medtronic, Inc. | Detecting posture sensor signal shift or drift in medical devices |
US9655677B2 (en) | 2010-05-12 | 2017-05-23 | Shifamed Holdings, Llc | Ablation catheters including a balloon and electrodes |
EP2568905A4 (en) | 2010-05-12 | 2017-07-26 | Shifamed Holdings, LLC | Low profile electrode assembly |
US8688200B2 (en) | 2010-10-29 | 2014-04-01 | Medtronic, Inc. | Ischemia detection and classification |
US8812102B2 (en) | 2011-05-23 | 2014-08-19 | Cardiac Pacemakers, Inc. | Sensor response delay for hemodynamic stability detection during arrhythmia |
US9020596B2 (en) | 2011-07-15 | 2015-04-28 | Cardiac Pacemakers, Inc. | Management of fusion beat detection during capture threshold determination |
US9907959B2 (en) | 2012-04-12 | 2018-03-06 | Medtronic, Inc. | Velocity detection for posture-responsive therapy |
US9737719B2 (en) | 2012-04-26 | 2017-08-22 | Medtronic, Inc. | Adjustment of therapy based on acceleration |
US20130289377A1 (en) | 2012-04-27 | 2013-10-31 | Medtronic, Inc. | Method and apparatus for cardiac function monitoring |
US10098694B2 (en) | 2013-04-08 | 2018-10-16 | Apama Medical, Inc. | Tissue ablation and monitoring thereof |
US10349824B2 (en) | 2013-04-08 | 2019-07-16 | Apama Medical, Inc. | Tissue mapping and visualization systems |
KR20150140760A (en) | 2013-04-08 | 2015-12-16 | 아파마 메디칼, 인크. | Cardiac ablation catheters and methods of use thereof |
US10220213B2 (en) | 2015-02-06 | 2019-03-05 | Cardiac Pacemakers, Inc. | Systems and methods for safe delivery of electrical stimulation therapy |
WO2016130477A2 (en) | 2015-02-09 | 2016-08-18 | Cardiac Pacemakers, Inc. | Implantable medical device with radiopaque id tag |
WO2016141046A1 (en) | 2015-03-04 | 2016-09-09 | Cardiac Pacemakers, Inc. | Systems and methods for treating cardiac arrhythmias |
CN108136186B (en) | 2015-08-20 | 2021-09-17 | 心脏起搏器股份公司 | System and method for communication between medical devices |
CN108136187B (en) | 2015-08-20 | 2021-06-29 | 心脏起搏器股份公司 | System and method for communication between medical devices |
WO2017040115A1 (en) | 2015-08-28 | 2017-03-09 | Cardiac Pacemakers, Inc. | System for detecting tamponade |
CN108136189B (en) | 2015-08-28 | 2021-10-15 | 心脏起搏器股份公司 | System for behavioral response signal detection and therapy delivery |
US10226631B2 (en) | 2015-08-28 | 2019-03-12 | Cardiac Pacemakers, Inc. | Systems and methods for infarct detection |
WO2017044389A1 (en) | 2015-09-11 | 2017-03-16 | Cardiac Pacemakers, Inc. | Arrhythmia detection and confirmation |
US10065041B2 (en) | 2015-10-08 | 2018-09-04 | Cardiac Pacemakers, Inc. | Devices and methods for adjusting pacing rates in an implantable medical device |
WO2017087549A1 (en) | 2015-11-16 | 2017-05-26 | Apama Medical, Inc. | Energy delivery devices |
JP6608063B2 (en) | 2015-12-17 | 2019-11-20 | カーディアック ペースメイカーズ, インコーポレイテッド | Implantable medical device |
US10905886B2 (en) | 2015-12-28 | 2021-02-02 | Cardiac Pacemakers, Inc. | Implantable medical device for deployment across the atrioventricular septum |
US10583303B2 (en) | 2016-01-19 | 2020-03-10 | Cardiac Pacemakers, Inc. | Devices and methods for wirelessly recharging a rechargeable battery of an implantable medical device |
WO2017136548A1 (en) | 2016-02-04 | 2017-08-10 | Cardiac Pacemakers, Inc. | Delivery system with force sensor for leadless cardiac device |
CN108883286B (en) | 2016-03-31 | 2021-12-07 | 心脏起搏器股份公司 | Implantable medical device with rechargeable battery |
US10328272B2 (en) | 2016-05-10 | 2019-06-25 | Cardiac Pacemakers, Inc. | Retrievability for implantable medical devices |
US10668294B2 (en) | 2016-05-10 | 2020-06-02 | Cardiac Pacemakers, Inc. | Leadless cardiac pacemaker configured for over the wire delivery |
CN109414582B (en) | 2016-06-27 | 2022-10-28 | 心脏起搏器股份公司 | Cardiac therapy system for resynchronization pacing management using subcutaneous sensing of P-waves |
US11207527B2 (en) | 2016-07-06 | 2021-12-28 | Cardiac Pacemakers, Inc. | Method and system for determining an atrial contraction timing fiducial in a leadless cardiac pacemaker system |
WO2018009392A1 (en) | 2016-07-07 | 2018-01-11 | Cardiac Pacemakers, Inc. | Leadless pacemaker using pressure measurements for pacing capture verification |
CN109475743B (en) | 2016-07-20 | 2022-09-02 | 心脏起搏器股份公司 | System for utilizing atrial contraction timing references in a leadless cardiac pacemaker system |
EP3500342B1 (en) | 2016-08-19 | 2020-05-13 | Cardiac Pacemakers, Inc. | Trans-septal implantable medical device |
EP3503970B1 (en) | 2016-08-24 | 2023-01-04 | Cardiac Pacemakers, Inc. | Cardiac resynchronization using fusion promotion for timing management |
WO2018039335A1 (en) | 2016-08-24 | 2018-03-01 | Cardiac Pacemakers, Inc. | Integrated multi-device cardiac resynchronization therapy using p-wave to pace timing |
US10758737B2 (en) | 2016-09-21 | 2020-09-01 | Cardiac Pacemakers, Inc. | Using sensor data from an intracardially implanted medical device to influence operation of an extracardially implantable cardioverter |
CN109803720B (en) | 2016-09-21 | 2023-08-15 | 心脏起搏器股份公司 | Leadless stimulation device having a housing containing its internal components and functioning as a terminal for a battery case and an internal battery |
WO2018057626A1 (en) | 2016-09-21 | 2018-03-29 | Cardiac Pacemakers, Inc. | Implantable cardiac monitor |
US10413733B2 (en) | 2016-10-27 | 2019-09-17 | Cardiac Pacemakers, Inc. | Implantable medical device with gyroscope |
EP3532159B1 (en) | 2016-10-27 | 2021-12-22 | Cardiac Pacemakers, Inc. | Implantable medical device delivery system with integrated sensor |
AU2017350759B2 (en) | 2016-10-27 | 2019-10-17 | Cardiac Pacemakers, Inc. | Implantable medical device with pressure sensor |
WO2018081275A1 (en) | 2016-10-27 | 2018-05-03 | Cardiac Pacemakers, Inc. | Multi-device cardiac resynchronization therapy with timing enhancements |
WO2018081133A1 (en) | 2016-10-27 | 2018-05-03 | Cardiac Pacemakers, Inc. | Implantable medical device having a sense channel with performance adjustment |
EP3532160B1 (en) | 2016-10-27 | 2023-01-25 | Cardiac Pacemakers, Inc. | Separate device in managing the pace pulse energy of a cardiac pacemaker |
EP3532158B1 (en) | 2016-10-31 | 2022-12-14 | Cardiac Pacemakers, Inc. | Systems for activity level pacing |
US10617874B2 (en) | 2016-10-31 | 2020-04-14 | Cardiac Pacemakers, Inc. | Systems and methods for activity level pacing |
US10583301B2 (en) | 2016-11-08 | 2020-03-10 | Cardiac Pacemakers, Inc. | Implantable medical device for atrial deployment |
CN109952129B (en) | 2016-11-09 | 2024-02-20 | 心脏起搏器股份公司 | System, device and method for setting cardiac pacing pulse parameters for a cardiac pacing device |
CN109963618B (en) | 2016-11-21 | 2023-07-04 | 心脏起搏器股份公司 | Leadless cardiac pacemaker with multi-mode communication |
US10881869B2 (en) | 2016-11-21 | 2021-01-05 | Cardiac Pacemakers, Inc. | Wireless re-charge of an implantable medical device |
CN109996585B (en) | 2016-11-21 | 2023-06-13 | 心脏起搏器股份公司 | Implantable medical device with magnetically permeable housing and induction coil disposed around the housing |
EP3541471B1 (en) | 2016-11-21 | 2021-01-20 | Cardiac Pacemakers, Inc. | Leadless cardiac pacemaker providing cardiac resynchronization therapy |
US10639486B2 (en) | 2016-11-21 | 2020-05-05 | Cardiac Pacemakers, Inc. | Implantable medical device with recharge coil |
US11207532B2 (en) | 2017-01-04 | 2021-12-28 | Cardiac Pacemakers, Inc. | Dynamic sensing updates using postural input in a multiple device cardiac rhythm management system |
EP3573708B1 (en) | 2017-01-26 | 2021-03-10 | Cardiac Pacemakers, Inc. | Leadless implantable device with detachable fixation |
WO2018140623A1 (en) | 2017-01-26 | 2018-08-02 | Cardiac Pacemakers, Inc. | Leadless device with overmolded components |
JP7000438B2 (en) | 2017-01-26 | 2022-01-19 | カーディアック ペースメイカーズ, インコーポレイテッド | Human device communication with redundant message transmission |
US10905872B2 (en) | 2017-04-03 | 2021-02-02 | Cardiac Pacemakers, Inc. | Implantable medical device with a movable electrode biased toward an extended position |
JP6953614B2 (en) | 2017-04-03 | 2021-10-27 | カーディアック ペースメイカーズ, インコーポレイテッド | Cardiac pacemaker with pacing pulse energy adjustment based on sensed heart rate |
GB2563440B (en) * | 2017-06-16 | 2019-06-05 | Cardiaccs As | Securing a sensor at the heart |
WO2019036600A1 (en) | 2017-08-18 | 2019-02-21 | Cardiac Pacemakers, Inc. | Implantable medical device with pressure sensor |
US10918875B2 (en) | 2017-08-18 | 2021-02-16 | Cardiac Pacemakers, Inc. | Implantable medical device with a flux concentrator and a receiving coil disposed about the flux concentrator |
US11235163B2 (en) | 2017-09-20 | 2022-02-01 | Cardiac Pacemakers, Inc. | Implantable medical device with multiple modes of operation |
US11185703B2 (en) | 2017-11-07 | 2021-11-30 | Cardiac Pacemakers, Inc. | Leadless cardiac pacemaker for bundle of his pacing |
US11813463B2 (en) | 2017-12-01 | 2023-11-14 | Cardiac Pacemakers, Inc. | Leadless cardiac pacemaker with reversionary behavior |
EP3717059A1 (en) | 2017-12-01 | 2020-10-07 | Cardiac Pacemakers, Inc. | Methods and systems for detecting atrial contraction timing fiducials within a search window from a ventricularly implanted leadless cardiac pacemaker |
WO2019108482A1 (en) | 2017-12-01 | 2019-06-06 | Cardiac Pacemakers, Inc. | Methods and systems for detecting atrial contraction timing fiducials and determining a cardiac interval from a ventricularly implanted leadless cardiac pacemaker |
WO2019108545A1 (en) | 2017-12-01 | 2019-06-06 | Cardiac Pacemakers, Inc. | Methods and systems for detecting atrial contraction timing fiducials during ventricular filling from a ventricularly implanted leadless cardiac pacemaker |
CN111556773A (en) | 2018-01-04 | 2020-08-18 | 心脏起搏器股份公司 | Dual chamber pacing without beat-to-beat communication |
US11529523B2 (en) | 2018-01-04 | 2022-12-20 | Cardiac Pacemakers, Inc. | Handheld bridge device for providing a communication bridge between an implanted medical device and a smartphone |
WO2019183512A1 (en) | 2018-03-23 | 2019-09-26 | Medtronic, Inc. | Vfa cardiac resynchronization therapy |
WO2019183507A1 (en) | 2018-03-23 | 2019-09-26 | Medtronic, Inc. | Av synchronous vfa cardiac therapy |
US11058880B2 (en) | 2018-03-23 | 2021-07-13 | Medtronic, Inc. | VFA cardiac therapy for tachycardia |
CN112770807A (en) | 2018-09-26 | 2021-05-07 | 美敦力公司 | Capture in atrial-to-ventricular cardiac therapy |
US11951313B2 (en) | 2018-11-17 | 2024-04-09 | Medtronic, Inc. | VFA delivery systems and methods |
CN109864740B (en) * | 2018-12-25 | 2022-02-01 | 北京津发科技股份有限公司 | Surface electromyogram signal acquisition sensor and equipment in motion state |
US11679265B2 (en) | 2019-02-14 | 2023-06-20 | Medtronic, Inc. | Lead-in-lead systems and methods for cardiac therapy |
US11697025B2 (en) | 2019-03-29 | 2023-07-11 | Medtronic, Inc. | Cardiac conduction system capture |
US11213676B2 (en) | 2019-04-01 | 2022-01-04 | Medtronic, Inc. | Delivery systems for VfA cardiac therapy |
US11712188B2 (en) | 2019-05-07 | 2023-08-01 | Medtronic, Inc. | Posterior left bundle branch engagement |
US11305127B2 (en) | 2019-08-26 | 2022-04-19 | Medtronic Inc. | VfA delivery and implant region detection |
US11559241B2 (en) | 2019-10-01 | 2023-01-24 | Pacesetter, Inc. | Methods and systems for reducing false declarations of arrhythmias |
US11813466B2 (en) | 2020-01-27 | 2023-11-14 | Medtronic, Inc. | Atrioventricular nodal stimulation |
US11911168B2 (en) | 2020-04-03 | 2024-02-27 | Medtronic, Inc. | Cardiac conduction system therapy benefit determination |
US11813464B2 (en) | 2020-07-31 | 2023-11-14 | Medtronic, Inc. | Cardiac conduction system evaluation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030013974A1 (en) * | 1998-08-07 | 2003-01-16 | Ananth Natarajan | Implantable myocardial ischemia detection, indication and action technology |
US7181268B2 (en) * | 2001-12-03 | 2007-02-20 | Medtronic, Inc. | Ischemia detection |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5365426A (en) * | 1987-03-13 | 1994-11-15 | The University Of Maryland | Advanced signal processing methodology for the detection, localization and quantification of acute myocardial ischemia |
US5010888A (en) | 1988-03-25 | 1991-04-30 | Arzco Medical Electronics, Inc. | Method and apparatus for detection of posterior ischemia |
US4877035A (en) | 1988-10-12 | 1989-10-31 | Trustees Of The University Of Pennsylvania | Measurement of the end-systolic pressure-volume relation using intraaortic balloon occlusion |
US5511553A (en) | 1989-02-15 | 1996-04-30 | Segalowitz; Jacob | Device-system and method for monitoring multiple physiological parameters (MMPP) continuously and simultaneously |
CA2078136A1 (en) | 1990-03-16 | 1991-09-17 | John M. Zanetti | Myocardial ischemia detection system |
EP0473070B1 (en) | 1990-08-24 | 1995-11-29 | Bozidar Ferek-Petric | Cardiac pacing systems with tensiometry |
US5271392A (en) | 1990-08-24 | 1993-12-21 | Siemens-Elema Ab | Method and apparatus for administering cardiac electrotherapy dependent on mechanical and electrical cardiac activity |
US5135004A (en) | 1991-03-12 | 1992-08-04 | Incontrol, Inc. | Implantable myocardial ischemia monitor and related method |
US5199428A (en) | 1991-03-22 | 1993-04-06 | Medtronic, Inc. | Implantable electrical nerve stimulator/pacemaker with ischemia for decreasing cardiac workload |
IT1245814B (en) | 1991-05-21 | 1994-10-18 | Sorin Biomedica Spa | RATE RESPONSIVE CARDIOSTIMULATOR DEVICE |
US5251621A (en) | 1991-12-18 | 1993-10-12 | Telectronics Pacing Systems, Inc. | Arrhythmia control pacer using skeletal muscle cardiac graft stimulation |
US5313953A (en) | 1992-01-14 | 1994-05-24 | Incontrol, Inc. | Implantable cardiac patient monitor |
US5330507A (en) | 1992-04-24 | 1994-07-19 | Medtronic, Inc. | Implantable electrical vagal stimulation for prevention or interruption of life threatening arrhythmias |
IT1256900B (en) | 1992-07-27 | 1995-12-27 | Franco Vallana | PROCEDURE AND DEVICE TO DETECT CARDIAC FUNCTIONALITY. |
US5628777A (en) | 1993-07-14 | 1997-05-13 | Pacesetter, Inc. | Implantable leads incorporating cardiac wall acceleration sensors and method of fabrication |
IT1260692B (en) | 1993-10-05 | 1996-04-22 | Sorin Biomedica Spa | DEVICE FOR DETERMINING THE MYOCARDIC FUNCTION AND ITS PROCEDURE. |
US5609612A (en) | 1993-10-05 | 1997-03-11 | Sorin Biomedica Cardio S.P.A. | Device for determining myocardial function and corresponding procedure and method |
US6077236A (en) * | 1994-06-07 | 2000-06-20 | Cunningham; David | Apparatus for monitoring cardiac contractility |
US5531768A (en) | 1995-02-21 | 1996-07-02 | Incontrol, Inc. | Implantable atrial defibrillator having ischemia coordinated intervention therapy and method |
DE69726599T2 (en) | 1996-01-08 | 2004-09-30 | Biosense Inc. | ELECTROMECHANICAL HEART DEVICE |
DE69727183T2 (en) | 1996-09-24 | 2004-11-04 | Xomed Surgical Products, Inc., North Jacksonville | Driven handpiece |
US5803084A (en) * | 1996-12-05 | 1998-09-08 | Olson; Charles | Three dimensional vector cardiographic display and method for displaying same |
SE9700181D0 (en) * | 1997-01-22 | 1997-01-22 | Pacesetter Ab | Ischemia detector and heart stimulator provided with such an ischemia detector |
SE9701122D0 (en) * | 1997-03-26 | 1997-03-26 | Pacesetter Ab | Medical implant |
SE9701121D0 (en) * | 1997-03-26 | 1997-03-26 | Pacesetter Ab | Implantable heart stimulator |
US5919210A (en) | 1997-04-10 | 1999-07-06 | Pharmatarget, Inc. | Device and method for detection and treatment of syncope |
SE9704312D0 (en) | 1997-11-24 | 1997-11-24 | Pacesetter Ab | Sensing of heart contraction |
US6171256B1 (en) * | 1998-04-30 | 2001-01-09 | Physio-Control Manufacturing Corporation | Method and apparatus for detecting a condition associated with acute cardiac ischemia |
US6217525B1 (en) * | 1998-04-30 | 2001-04-17 | Medtronic Physio-Control Manufacturing Corp. | Reduced lead set device and method for detecting acute cardiac ischemic conditions |
US6024705A (en) * | 1998-11-06 | 2000-02-15 | Bioacoustics, Inc. | Automated seismic detection of myocardial ischemia and related measurement of cardiac output parameters |
US6128526A (en) * | 1999-03-29 | 2000-10-03 | Medtronic, Inc. | Method for ischemia detection and apparatus for using same |
US6115628A (en) * | 1999-03-29 | 2000-09-05 | Medtronic, Inc. | Method and apparatus for filtering electrocardiogram (ECG) signals to remove bad cycle information and for use of physiologic signals determined from said filtered ECG signals |
US6077277A (en) | 1999-04-05 | 2000-06-20 | Starion Instruments, Inc. | Suture welding device |
-
2001
- 2001-08-30 US US09/945,179 patent/US6937899B2/en not_active Expired - Lifetime
-
2002
- 2002-08-20 WO PCT/US2002/026403 patent/WO2003020366A1/en not_active Application Discontinuation
-
2005
- 2005-08-30 US US11/215,710 patent/US20060009811A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030013974A1 (en) * | 1998-08-07 | 2003-01-16 | Ananth Natarajan | Implantable myocardial ischemia detection, indication and action technology |
US7181268B2 (en) * | 2001-12-03 | 2007-02-20 | Medtronic, Inc. | Ischemia detection |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8016783B2 (en) | 2003-08-21 | 2011-09-13 | Cardiac Pacemakers, Inc. | Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure |
US20080091138A1 (en) * | 2003-08-21 | 2008-04-17 | Cardiac Pacemakers, Inc. | Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure |
US20100081948A1 (en) * | 2004-06-18 | 2010-04-01 | Pastore Joseph M | Method and apparatus for localizing myocardial infarction during catheterization |
US9008746B2 (en) | 2004-06-18 | 2015-04-14 | Cardiac Pacemakers, Inc. | Method and apparatus for localizing myocardial infarction during catheterization |
US8538520B2 (en) | 2005-09-06 | 2013-09-17 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression for cardiac protection |
US7774057B2 (en) | 2005-09-06 | 2010-08-10 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression for cardiac protection |
US20070054871A1 (en) * | 2005-09-06 | 2007-03-08 | Pastore Joseph M | Method and apparatus for device controlled gene expression for cardiac protection |
US7751882B1 (en) * | 2005-12-21 | 2010-07-06 | Pacesetter, Inc. | Method and system for determining lead position for optimized cardiac resynchronization therapy hemodynamics |
US20070150015A1 (en) * | 2005-12-23 | 2007-06-28 | Yi Zhang | Implantable cardiac device with ischemia response capability |
US7774061B2 (en) | 2005-12-23 | 2010-08-10 | Cardiac Pacemakers, Inc. | Implantable cardiac device with ischemia response capability |
US8781566B2 (en) * | 2006-03-01 | 2014-07-15 | Angel Medical Systems, Inc. | System and methods for sliding-scale cardiac event detection |
US20080188763A1 (en) * | 2006-03-01 | 2008-08-07 | Michael Sasha John | System and methods for sliding-scale cardiac event detection |
US8000780B2 (en) | 2006-06-27 | 2011-08-16 | Cardiac Pacemakers, Inc. | Detection of myocardial ischemia from the time sequence of implanted sensor measurements |
US20070299356A1 (en) * | 2006-06-27 | 2007-12-27 | Ramesh Wariar | Detection of myocardial ischemia from the time sequence of implanted sensor measurements |
US20100312130A1 (en) * | 2006-06-27 | 2010-12-09 | Yi Zhang | Graded response to myocardial ischemia |
US20080081354A1 (en) * | 2006-10-02 | 2008-04-03 | Cardiac Pacemakers, Inc. | Devices, vectors and methods for inducible ischemia cardioprotection |
US20080082135A1 (en) * | 2006-10-02 | 2008-04-03 | Cardiac Pacemakers, Inc. | Method and apparatus for identification of ischemic/infarcted regions and therapy optimization |
US8219210B2 (en) | 2006-10-02 | 2012-07-10 | Cardiac Pacemakers, Inc. | Method and apparatus for identification of ischemic/infarcted regions and therapy optimization |
US8489204B2 (en) | 2006-10-02 | 2013-07-16 | Caridac Pacemakers, Inc. | Method and apparatus for identification of ischemic/infarcted regions and therapy optimization |
US8014863B2 (en) | 2007-01-19 | 2011-09-06 | Cardiac Pacemakers, Inc. | Heart attack or ischemia detector |
US20080177194A1 (en) * | 2007-01-19 | 2008-07-24 | Cardiac Pacemakers, Inc. | Heart attack detector |
US20080177156A1 (en) * | 2007-01-19 | 2008-07-24 | Cardiac Pacemakers, Inc. | Ischemia detection using pressure sensor |
US7949388B1 (en) | 2007-03-16 | 2011-05-24 | Pacesetter, Inc. | Methods and systems to characterize ST segment variation over time |
US7930017B1 (en) | 2007-05-25 | 2011-04-19 | Pacesetter, Inc. | Method and system for trending variation in coronary burden across multiple heart rate ranges |
US7865232B1 (en) | 2007-08-07 | 2011-01-04 | Pacesetter, Inc. | Method and system for automatically calibrating ischemia detection parameters |
US20090171413A1 (en) * | 2007-08-31 | 2009-07-02 | Marco Zenati | Implantable device, system including same, and method utilizing same |
WO2009029943A1 (en) * | 2007-08-31 | 2009-03-05 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Implantable device, system including same, and method utilizing same |
US7725171B1 (en) | 2007-08-31 | 2010-05-25 | Pacesetter, Inc. | System and method for tracking ST shift data utilizing histograms |
US20090099467A1 (en) * | 2007-10-15 | 2009-04-16 | Pacesetter, Inc. | Method and system for tracking quality of life in patients with angina |
US8469897B2 (en) | 2007-10-15 | 2013-06-25 | Pacesetter, Inc. | Method and system for tracking quality of life in patients with angina |
US20100016916A1 (en) * | 2008-07-16 | 2010-01-21 | Shantha Arcot-Krishnamurthy | Apparatus and methods for treatment of atherosclerosis and infarction |
US20100016913A1 (en) * | 2008-07-16 | 2010-01-21 | Shantha Arcot-Krishnamurthy | Intermittent pacing therapy for angina and disease prevention |
US20100030034A1 (en) * | 2008-07-31 | 2010-02-04 | Schulhauser Randal C | Apparatus and Method for Detecting Cardiac Events |
US9545215B2 (en) * | 2008-07-31 | 2017-01-17 | Medtronic, Inc. | Apparatus and method for detecting cardiac events |
US20100114231A1 (en) * | 2008-11-05 | 2010-05-06 | Pacesetter, Inc. | Methods and systems to monitor ischemia |
US8467862B2 (en) | 2010-03-30 | 2013-06-18 | Pacesetter, Inc. | Systems and methods related to ST segment monitoring by an implantable medical device |
US20130053907A1 (en) * | 2011-08-23 | 2013-02-28 | Jens Kirchner | Comparison of right-ventricular and left-ventricular contraction using an accelerometer in an artery close to the heart |
US8862231B2 (en) * | 2011-08-23 | 2014-10-14 | Biotronik Se & Co. Kg | Comparison of right-ventricular and left-ventricular contraction using an accelerometer in an artery close to the heart |
Also Published As
Publication number | Publication date |
---|---|
US20030045805A1 (en) | 2003-03-06 |
US6937899B2 (en) | 2005-08-30 |
WO2003020366A1 (en) | 2003-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6937899B2 (en) | Ischemia detection | |
US7181268B2 (en) | Ischemia detection | |
EP1423163B1 (en) | System for detecting myocardial ischemia | |
EP2242538B1 (en) | Methods of monitoring hemodynamic status for ryhthm discrimination within the heart | |
EP1971395B1 (en) | System for interpreting hemodynamic data incorporating patient posture information | |
US10758737B2 (en) | Using sensor data from an intracardially implanted medical device to influence operation of an extracardially implantable cardioverter | |
EP1572296B1 (en) | Ischemia detection based on cardiac conduction time | |
US8126553B2 (en) | Sensing integrity determination based on cardiovascular pressure | |
US7130681B2 (en) | Use of accelerometer signal to augment ventricular arrhythmia detection | |
JP3959025B2 (en) | Method and apparatus for determining mean pulmonary artery pressure | |
US10118042B2 (en) | Lead integrity testing triggered by sensed asystole | |
US8396543B2 (en) | Storage of data for evaluation of lead integrity | |
US9907962B2 (en) | Arrhythmia prediction based on heart rate turbulence | |
EP2397185B1 (en) | Blood pressure measurement with implantable medical device | |
CN111432875A (en) | Method and system for detecting atrial contraction timing references and determining cardiac intervals from a ventricular-implantable leadless cardiac pacemaker | |
CN111417432A (en) | Leadless cardiac pacemaker with involution behavior |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |